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ABSTRACT 
 
Homeostasic balance of one-carbon metabolism is highly dependent upon derivatives of 
folate and is vital for the prevention of multiple disease states, including vascular disease, 
birth defects, neurological disorders, and cancer.  Homocysteine, a non-protein forming 
amino acid, accumulates in the absence of 5-methyltetrahydrofolate and represents both a 
marker for reduced cellular methylation potential and elicitor of pathogenesis (Cattaneo, 
1999).  In addition to cofactors like folate, vitamin B6, B12, and B2, various bioactive 
compounds are believed to influence the same cellular processes either directly or 
indirectly (Strain et al., 2004).  The isoflavone genistein exhibits estrogen-like properties 
and has been implicated in the prevention of various diseases, including those involving 
hyperhomocysteinemia (Marini et al., 2009).  Genistein has been shown to stably alter 
DNA methyltransferase and histone acetyltransferase activities independently of folate 
(Dolinoy et al, 2006; Li et al., 2009).  This study was conducted to determine if genistein 
could modulate one-carbon metabolism during diet-induced folate deficiency.  
Specifically, we aimed to determine whether genistein is able to prevent 
hyperhomocysteinemia caused by moderate folate deficiency and classify any changes in 
relevant enzyme function, including those related to transmethylation, remethylation, and 
transsulfuration pathways, as well as alterations in genomic DNA methylation patterns. 
Administration of genistein (300 mg/kg diet) reduced plasma homocysteine 
concentrations in rats fed a folate-deficient diet in three independent studies without 
consistent alterations in enzyme activity or expression. Attenuation of plasma 
homocysteine was similar and occurred independently across each study at 10, 24, and 59 
d of supplementation. There were no differences in genomic DNA methylation patterns 
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or measured hepatic transmethylation, remethylation, and transsulfuration enzymes as 
determined by analysis of enzyme expression and activity. Future research is warranted 
to determine the specific actions of genistein related to its ability to mediate one-carbon 
metabolism during moderate folate deficiency.
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CHAPTER 1.  GENERAL INTRODUCTION 
Thesis Organization 
  The thesis is composed of three chapters that include a general introduction, the 
description of experiments, and general conclusions.  Chapter one consists of a general 
introduction describing the overall research question addressed and a literature review 
that encompasses relevant research regarding one-carbon metabolism, the importance of 
homocysteine, epigenetics, and how genistein may interacts with these systems. The 
experiments are discussed in chapter two, including methods and results for related 
studies.  A general conclusion of the experiments is given in chapter three.  References 
cited in all three chapters follow Chapter 3.  
Description of Research Questions 
 The research aim for this thesis was to examine the effects of dietary genistein on 
perturbations in one-carbon metabolism due to diet-induced folate deficiency.  
Populations regularly consuming soy foodstuffs containing isoflavones exhibit a lower 
incidence of cardiovascular disease and estrogen-responsive cancers (e.g., breast and 
prostate cancers) (Sacks et al., 2006). However, many other dietary constituents (i.e., 
macro/micro-nutrients and bioactive compounds) vary between cultures, as do lifestyles 
and genetic predispositions to disease (Fang et al., 2007).  Citizens of industrialized 
countries, like the United States, consume on average a fraction of the soy-based food 
products compared to people living in countries such as China and Japan. Individuals 
migrating from these countries to the United States are at increased risk for developing 
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disease (i.e., obesity, diabetes, CVD, and certain cancers), possibly related to changes in 
dietary intake (Penza et al., 2007).  
 Population data attributing isoflavone intake to health promotion are poorly 
defined, as humans do not consume pure dietary constituents nor are diets constant within 
a given population.  The purified isoflavone genistein, a 17-β-estradiol-like molecule, has 
shown various biological effects in cell-culture and animal models.  Genistein displays 
paradoxical activity, as an agonist and antagonist to endogenous estrogen-receptors (e.g., 
ER-α and ER-β). Genistein has been shown to influence a diverse range of cellular 
pathways where dosage, model, and duration of treatment can produce variable, 
sometimes polar effects (Sacks et al., 2006).   
 One-carbon metabolism includes a series of interrelated pathways that are 
responsible for the production and regulation of proteins, hormones, phospholipids, and 
nucleic acids.  S-adenosylmethionine (SAM) is the major biological methyl-donor for all 
organisms (Wagner, 1995).  Upon transferring a methyl group, SAM forms 
homocysteine, a non-protein forming amino acid, which can accumulate if not 
remethylated to back methionine or degraded to cysteine via the transsulfuration 
pathway.  Hyperhomocysteinemia is associated with various pathologies, including 
cardiovascular disease, neural tube defects, and certain cancers (Aguilar et al., 2004).  
Homocysteine represents a marker of cellular methyl-potential, which influences among 
other things DNA-methylation, an epigenetic mechanism that modulates transcription, 
translation, differentiation, proliferation, and apoptosis (Fux et al., 2005).  The folate 
coenzyme, 5-methyltetrahydrofolate, is responsible for remethylating homocysteine to 
methionine in concert with the vitamin B12 dependent enzyme methionine synthase.  
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Chronic folate deficiency poses severe metabolic consequences including development of 
various diseases due to its role in nucleic acid synthesis, DNA methylation, and 
methionine metabolism (Fux et al., 2005).     
 Genistein has been shown to influence DNA methylation in estrogen-responsive 
tissues.  However, the specific interactions are not completely understood, particularly in 
regards to folate metabolism, which governs the activity of the DNA-methyltransferase 
(i.e., Dnmt 1, 3a, and 3b) enzymes (Day et al., 2002).  
My research aim was to investigate the specific actions of pure genistein during 
moderate diet-induced folate deficiency.  Our diet model incorporated an amount of 
genistein equivalent to what an individual could consume with either a diet rich in soy 
foodstuffs or by supplementation.  Using a folate-restricted system, without severe 
interventions, such as antibiotic administration (e.g., sulfamethoxazole) or choline 
restriction, we modeled a subset of the population exhibiting perturbations of folate 
metabolism due to either inadequate folate intake or altered metabolism, common in 
individuals with polymorphisms of genes regulating folate metabolism (Bailey and 
Gregory, 1999).    
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Literature Review  
Folate Metabolism 
 Folate (vitamin B9) is a common name that describes a diverse group of molecules 
derived from tetrahydrofolate (THF).  One-carbon metabolism describes reactions 
utilizing folate coenzymes to donate or accept one-carbon units (Bailey and Gregory, 
1999).  Fully oxidized folate or folic acid (pteroylmonoglutamate), is comprised of a 2-
amino-4-hydroxy-pteridine moiety bound to p-aminobenzoylglutamic acid by a 
methylene group (Wagner, 1995) (Figure 1).  Plants synthesize a reduced form of folate 
(7,8-dihydrofolate), which is sensitive to food processing methods such as boiling. In the 
animal, the majority of tissue folates are polyglutamate species.  Monoglutamate species 
are not retained within the cell and are transported out of the cell to maintain normal 
cellular folate metabolism, which is under tight control (Stipanuk, 2006).  Folate 
monoglutamates are absorbed in the small intestine by a folate transmembrane protein, 
encoded by the reduced folate carrier gene (RFC-1).  Although protein-mediated 
absorption is most common, folate monoglutamates can diffuse across the enterocyte at 
high concentrations during periods of supplementation with folic acid.  Whole foodstuffs, 
such as vegetables, when digested provide in the polyglutamate form of folate. In the 
small intestine, the brush boarder enzyme γ-glutamylhydrolase cleaves polyglutamates 
into monoglutamates prior to absorption across the enterocyte.  Although the enterocyte 
can metabolize folate, the majority of absorbed monoglutamates remain unchanged as 
reflected in the portal circulation.  In mammals, cells are unable to transfer folate 
molecules containing more than two glutamate moieties.  The major circulating folates 
are pteroylmonoglutamates, of which the primary form is 5-methyltetrahydrofolate, the 
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major cytosolic form in mammalian tissues (Wagner, 1995).  Certain tissues exhibit 
affinity for folate uptake, including the proximal tubule of the kidney, the choroid plexus, 
the placenta, and erythropoietic cells. This phenomenon, mediated by folate-binding 
proteins, highlights both functional and protective roles folate provides in specific tissues.  
The folate coenzyme pool reflects the quality of ingested folate and also the rate of folate 
loss through urine and feces (Bailey and Gregory, 1999).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.   Cellular folate metabolites. Taken from Blom et al., 2006.  
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 In industrialized countries, humans consume an average of 5-10 mmoles of 
methyl groups daily from dietary folates (Niculescu and Zeisel, 2002).  The most 
common sources of dietary folate include vegetables (i.e., spinach, asparagus, peas, 
broccoli, beets), fortified grain products (i.e., cereals, bread, pasta), fruits (i.e., oranges, 
cantaloupe, grapefruit, strawberries), and organ meats (e.g., liver).   The recommended 
daily folate requirement of 400 µg, based on the Dietary Reference Intakes (DRIs) 
established by the Institute of Medicine (National Academy of Sciences), satisfies the 
folate requirement for 97-98% of all healthy individuals.  Dietary folates are ingested and 
absorbed in various forms.  Therefore, the RDA for folate is based on an equilibration 
standard called the Dietary Folate Equivalent (DFE), where 1 DFE is equivalent to 1 µg 
of food folate or 0.6 µg of folic acid derived from supplements or fortified foods.  The 
dietary intake range for folate (µg DFE/day) considers age and physiological status 
(Table 1).  
Table 1.1.  Range of dietary folate equivalents (µg DFE/day) based on age and 
physiological status (Bailey and Gregory, 1999; Food and Nutrition Board, 2000). 
Age 
Months (mo) 
and Years (y) 
Males and 
Females 
(µg DFE/day) 
Pregnancy 
(µg DFE/day) 
Lactation 
(µg DFE/day) 
0-6 mo 65   
7-12 mo  80   
1-3 y 150-300 * * 
4-8 y 200-400 * * 
9-13 y 300-600 * * 
14-18 y 400-800 600-800 500-800 
≥ 19 y 400-1000 600-1000 500-1000 
  
Folate Fortification 
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 In 1998, the FDA required that folic acid be added through fortification to cereals, 
flours, rice, pasta, and other grain products in the United States; there was overwhelming 
evidence that supplementation with 800 µg of folic acid largely negated neural tube 
defects (NTDs) including spina bifida and anencephaly in the offspring of women of 
child-bearing age (Beaudin and Stover, 2007).  Further impetus to the initiative was 
realized because of the general knowledge that women often do not realize they are 
pregnant until weeks after conception and neural tube closure occurs at 4 weeks into 
pregnancy.  The worldwide incidence of NTD(s) ranges from 0.5 to 60 per 10,000 live 
births (Beaudin and Stover, 2007).  The association between NTD(s) and folate status 
was discovered in the 1960s when Hibbard and colleagues found higher concentration of 
formiminoglutamic acid in the urine of mothers birthing children with CNS defects, a 
biomarker of perturbed folate metabolism (Johnstone et al., 1965; Beaudin and Stover, 
2007).  Data from the National Health and Nutrition Examination Survey have 
documented a substantial increase in population blood folate levels between 1988-1994 
and again from 1999-2000 (McDowell et al., 2008). As a parameter, serum folate is a 
reflection of recent folate intake, whereas erythrocyte folate represents long-term folate 
status as tissue folate pools turn over roughly every 100 days, as do erythrocytes.  
Unfortified populations exhibit plasma folate concentrations in the range of 10-30 ng/ml 
(Stipanuk, 2006).  In 2006, the median erythrocyte folate concentration in individuals 
over 4 years of age was 266 ng/ml and serum folate concentration was 12.2 ng/ml.  In 
2006, the prevalence of folate deficiency, defined as either an erythrocyte folate 
concentration < 140 ng/ml or serum concentrations < 3 ng/ml was found to be 4.5% and 
0.5% respectively in women of child-bearing age (McDowell et al., 2008).  Folate 
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fortification has resulted in a 19-38% reduction in NTD(s) cases in the United States.  
However, within certain subsets of the population, including Hispanic populations, 
dietary fortification has not substantially reduced the risk of NTD(s). Other groups at risk 
of developing folate deficiency include the morbidly obese (BMI > 50), the elderly, 
alcoholics, celiacs, and those with polymorphic variations in genes regulating folate 
metabolism (Matsuo et al., 2005).    
Folate Fortification Risks 
 Folate supplementation also poses risks in populations residing in certain 
geographical areas, such as the malaria endemic regions of sub-Saharan Africa. A cohort 
intervention trial termed the Pemba study, conducted in Pemba (Tanzania) and also in 
Nepal, aimed to reduce cases of anemia in children by providing folic acid and iron 
supplementation (Sazawal et al., 2006).  Although the prevalence of anemia was reduced 
in the child population of Nepal, the trial in Pemba was forfeited due to increased 
morbidity and mortality within the study group. Further investigation concluded that 
malaria, endemic in Tanzania and non-existent in Nepal, was benefiting from bolus 
intakes of folic acid and iron, enhancing DNA turnover and, subsequently increasing 
parasitemia (Sazawal et al., 2006).   
 In the industrialized nations, where both food and supplemented folates are easily 
accessed, unknown side effects may exist, particularly related to cancer development and 
progression.  Many chemotherapeutic agents target folate metabolism. 5-fluorouracil, a 
cellular S-phase specific drug, interferes with thymidylate synthase, which requires 5,10-
methylenetetrahydrofolate as a substrate, preventing the conversion of deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) (Backus et al., 
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2000).  In doing so, neoplastic cells become apoptotic due to an inherently high rate of 
replication and requirement for DNA synthesis (Maruti et al., 2009).  Methotrexate also 
interferes with folate metabolism by inhibiting dihydrofolate reductase, which converts 
dihydrofolate (DHF) to tetrahydrofolate (THF), blocking DNA, RNA, and ultimately 
protein synthesis.  Folic acid supplementation may interfere with the actions of these 
chemotherapeutic agents and also promote cancer development by enhancing DNA 
turnover and proliferation (Maruti et al., 2009).  However, suboptimal folate status prior 
to administration of these cytotoxic agents increases the risk of developing hematological 
and non-hematological toxicity upon treatment (Backus et al., 2000). Therefore, folate 
may have paradoxical effects regarding cancer development, both as a preventative and a 
promoter.     
One-carbon Metabolism 
 Folate metabolism occurs in both the mitochondria and cytosol, where 
tetrahydrofolates are stored as polyglutamates by the enzyme folylpolyglutamate 
synthetase (Shane, 1989).  The polyglutamyl form of THF is the central folate molecule 
in cellular metabolism (Bailey and Gregory, 1999).  The pyridoxal phosphate (PLP)-
dependent enzyme, serine hydroxymethyltransferase (SHMT), catalyzes a one-carbon 
transfer from serine to THF, forming 5,10-methyleneTHF and glycine.  The enzyme 
methylenetetrahydrofolate reductase (MTHFR) irreversibly converts a potion of the 5,10-
methyleneTHF to 5-methylTHF, which is utilized solely for the remethylation of 
homocysteine.  
 Cellular polyglutamate synthesis favors tetrahydrofolate as the substrate. 
Therefore, 5-methyl-derivatives are converted to tetrahydrofolate prior to glutamate 
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addition by methionine synthase or exported to the circulation to maintain cellular 
homeostasis.  Cytosolic folate metabolism includes purine biosynthesis, methionine 
metabolism, and thymidylate synthesis. Within the mitochondria, numerous one-carbon 
metabolites and cofactors undergo formation and regulation, the major products formed 
being formate and glycine from serine (Beaudin and Stover, 2007).  Mitochondrial folate 
is largely 10-formyl-THF, which is required for purine biosynthesis.  Cytosolic folates 
are bound to either glycine-N-methyltransferase (GNMT) or 10-formyltetrahydrofolate 
dehydrogenase.  The enzyme GNMT regulates both the supply and utilization of cellular 
methyl-groups by modulating the folate-dependent one-carbon supply (Rowling et al., 
2002).  GNMT catalyzes the methylation of glycine to sarcosine, which functions in 
diverting excess methyl groups away from transmethylation when cellular folate and 
methyl groups exceed adequacy (Rowling et al., 2002).  During periods of folate 
deficiency GNMT activity is increased, allowing optimization of the folate-
transmethylation pool (Nieman et al., 2004).  GNMT activity is regulated in response to 
cellular 5-methylTHF concentrations, a reflection of MTHFR allosteric regulation by S-
adenosylmethionine. GNMT activity is also regulated through posttranslational 
modification by phosphorylation (Nieman et al., 2004).   
 S-adenosylmethionine (SAM) is the primary methyl donor for all living 
organisms.  In plants, SAM is required for ethylene production to mature fruit and in 
mammals SAM methylates guanidinoacetate to produce creatine, which functions to store 
high-energy phosphate.  In humans, SAM serves as the methyl donor for hundreds of 
reactions, including the methylation of DNA, RNA, proteins, phospholipids, 
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neurotransmitters, and hormones and also functions to regulate cell proliferation, 
differentiation, and apoptosis (Lu and Mato, 2008).   
Transmethylation 
 In a two-part reaction, methionine is converted to SAM by methionine 
adenosyltransferase (MAT).  Initially, adenosine triphosphate (ATP) and methionine are 
converted to SAM and tripolyphosphate by MAT.  The tripolyphosphate is hydrolyzed to 
orthophosphate and pyrophosphate, at which point the remaining phosphate is removed 
from the adenosine by a subsequent MAT reaction.  The genes MAT1A and MAT2A 
encode the MAT enzymes II, III, and I, which are highly expressed in mammalian 
hepatocytes and other tissues (Prudova, 2005).  Within the cell, SAM regulates both 
MAT1a and MAT2A expression through an unknown feedback mechanism in an 
opposing fashion (Grillo and Colombatto, 2008; Martinez-Chantar et al., 2003).  When 
sufficient SAM is formed, MAT2A expression is downregulated and SAM production is 
decreased. The cellular availability of methionine also regulates MAT2A expression, and 
its restriction favors conservation of SAM via increased half-life of MAT2A mRNA 
through the methionine salvage pathway where methylthioadenosine (MTA), a product of 
transmethylation in polyamine synthesis, is recycled to methionine to maintain cellular 
SAM homeostasis (Martinez-Chantar, 2003).  
 The transmethylation pathway, which transfers one-carbon moieties from SAM to 
various acceptor molecules, is vital for a number of cellular processes (Figure 1.2).  SAM 
irreversibly donates a methyl-group to a methyl-acceptor (R-CH3) molecule forming S-
adenosylhomocysteine (SAH), which is reversibly hydrolyzed to homocysteine by SAH-
hydrolase (SAHH).  The one-carbon moiety attached to the sulfur atom of methionine 
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serves as the donated methyl group.  The high-energy sulfonium ion of SAM promotes 
nucleophilic attack by the attached carbons, promoting the major SAM-dependent 
reactions: transmethylation, transsulfuration, and aminopropylation (Lieber and Packer, 
2002).  SAM-dependent reactions are strongly inhibited by increases in cellular SAH.  
Therefore, removal of SAH and homocysteine is essential to maintain normal cellular 
methyl-potential (Lieber and Packer, 2002). The R-CH3(s) include an array of cellular 
constituents including, guanidinoacetate, phosphatidylethanolamine (PE), 5’-cytosines of 
DNA, and polyamines.  The formation of phosphatidylcholine (PC) from PE and creatine 
from guanidinoacetate collectively consume upwards of 80% of SAM-derived methyl 
groups, with the remaining 20% being divided among over 100+ reactions.  
Figure 1.2.  Folate and one-carbon metabolism pathway (Taken from Lamprecht and 
Lipkin, 2003).   
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Homocysteine and Disease  
 Vigneaud and Dyer (1932) first classified “homocysteine” and “homocystine,” 
reduced (sulfhydryl) and oxidized (disulfide) non-protein amino acid molecules, 
homologous to cysteine and cystine with the addition of one methylene group (Yap, 
2005).   Homocysteine (-SCH2CH2CH(NH2)COOH) can refer to both free and bound 
homocysteine, including homocystine, S-adenosylhomocysteine, homocysteine-cysteine, 
and other Homocysteine-bound proteins that form a free thiol-homocysteine upon 
cleavage of the connecting disulfide bond (Mudd, 2000).  Total homocysteine (tHcy) 
includes both free and bound homocysteine and is a quantification of all homocysteine 
after reductive cleavage from bound constituents within a sample (i.e., urinary tHcy, 
hepatocyte tHcy, and plasma tHcy) (Martinez-Chantar et al., 2003).  Cysteine, a 
conditionally essential amino acid, can be formed from methionine-derived homocysteine 
via the transsulfuration pathway (Yap, 2005).  
 Hyperhomocysteinemia is an aberrant increase in circulating plasma and serum 
homocysteine concentration (Cattaneo, 1999). A moderately elevated plasma 
homocysteine concentration (15 µmol/L) is considered to be an independent risk factor 
for cardiovascular disease (CVD) including, stroke, myocardial infarction, venous 
thrombosis, and peripheral artery disease (Khandanpour et al., 2009).  
Hyperhomocysteinemia is believed to exist in 15% of the general population and in over 
50% of vascular patients (Spark et al., 2003). A 5 µmol/L increase in plasma 
homocysteine in women and men increases the risk of developing coronary heart disease 
by 60% and 80%, respectively (Spark et al., 2003); however, it has not been established 
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in humans if plasma homocysteine reflects intracellular homocysteine or the underlying 
pathogenesis (Cattaneo, 1999).  Homocysteine has been linked to increased vascular 
endothelial cell dysfunction by decreasing endothelin-1 biosynthesis, increasing 
inflammation and promoting thrombosis by up-regulating the coagulation cascade (i.e., 
platelet aggregation, fibrinolysis, increased vascular endothelial growth factor 
expression) (Aguilar et al., 2004). Homocysteine initiates signal-transduction induced 
oxidative damage by upregulating metalloproteinases through the activation of mitogen-
activated protein kinases (i.e., ERK, JNK, and p38) (Moshal et al., 2006).  Homocysteine 
also induces endothelial cell dysfunction by disrupting endothelial nitric oxide synthase 
(eNOS) synthesis and AP-1 signaling pathways (e.g., apoptosis).  The production of SAH 
inhibits DNA methylation in endothelial cells but not vascular smooth muscle cells 
(VSMC) (Huang et al., 2008); however, homocysteine activates NF-kB, stimulating the 
production of proinflammatory cytokines and differentiation of VSMC.  Homocysteine 
promotes lipid/LDL oxidation through the production of hydrogen peroxide in the 
presence of copper and can form highly reactive –NH-CO- adducts, promoting cellular 
damage.  
Beyond CVD, hyperhomocysteinemia is also associated with neural tube defects, 
low birth weight, renal disease, diabetes, neurological disorders, osteoporosis, and 
various forms of cancer.  Epidemiological evidence relating homocysteine to chronic 
disease has not defined whether its elevation induces, exacerbates, or serves as a marker 
for disease. Acute plasma homocysteine loading (65.1 µM) in healthy men was not found 
to change the methyl-potential or DNA methylation status in isolated lymphocytes (Fux 
et al., 2005); therefore, the detrimental effects of homocysteine are more strongly 
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associated with chronic elevations.  Men generally display higher plasma homocysteine 
concentrations compared to women, and although this discrepancy is reduced upon the 
onset of menopause, it persists in the elderly.  
 Although the specific mechanisms underlying homocysteine mediated CVD are 
not well established, multiple relationships are believed to exist related to its action as an 
oxidant including endothelium dysfunction, procoagulant actions (thrombosis), arterial 
stiffness, thickness, and immune modulation via inflammation (Strain et al., 2004).  A 
decreased methyl potential within a cell, reflected by increased plasma homocysteine 
concentrations, can directly influence pathogenesis via alterations of the epigenome 
(discussed later).  Elevated plasma homocysteine and S-adenosylhomocysteine (SAH) 
concentrations in elderly CVD patients coincide with leukocyte global hypomethylation 
(Castro et al., 2003; Strain et al., 2004). 
Preventing Hyperhomocysteinemia 
 Although chronic elevation of homocysteine often coincides with complex 
pathogenesis in humans, a number of polymorphisms in homocysteine re-methylation 
and transsulfuration pathways exist that can interfere with optimal methyl-group 
metabolism (Verhoef, 1996).  Deficiencies in cofactors required for transmethylation, 
remethylation and transsulfuration including folate (B9), cobolamin (B12), pyrodoxine 
(B6), riboflavin (B2), and the methyl-donors choline and methionine contribute to elevated 
homocysteine but also perturb numerous cellular reactions, which in turn, exacerbate the 
risk of developing chronic disease (Verhoef, 1996).  Supplementation with folic acid 
provides the most effective approach for reducing plasma homocysteine concentrations.  
A folate intake of 400 µg/d provides 90% of the maximal decrease of homocysteine (Van 
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Oort et al., 2003).  When combined with vitamin B12 (0.5 mg/d) an additional 7% 
reduction of homocysteine over the 25% reduction by folic acid supplementation occurs, 
arguing that although folic acid alone is the most effect combatant against 
hyperhomocysteinemia, combination therapy may be valuable for certain populations 
(Strain et al., 2004).  Optimizing folate status through supplementation with folic acid 
alone can mask vitamin B12 (cobalamin) deficiency.  
Cobolamin (Vitamin B12)  
 Cobolamin includes a group of molecules with the biological activity of vitamin 
B12.  Vitamin B12 is required for two major metabolic reactions.  However, its absence 
significantly affects the overall physiology of an organism.   The coenzyme forms of 
cobalamin include free Co1+ or cob(I)alamin, 5’-deoxyadenosylcob(III)alamin, and 
methyl-cob(III)alamin.  Vitamin B12 functions as a coenzyme for the conversion of 
malonyl-CoA to succinyl-CoA by the mitochondrial enzyme methyl-malonyl-CoA 
mutase during oxidative phosphorylation.  In addition, vitamin B12 serves as a cofactor 
(methyl-cob(III)alamin) for the cytosolic enzyme methionine synthase, which forms 
endogenous methionine from homocysteine via the folate-dependent one-carbon pool.  In 
this reaction, the methyl group is transferred from the substrate, 5-methylTHF to the 
vitamin B12-coenzyme and finally to homocysteine to produce methionine.  By donating 
its methyl-group, 5-methylTHF is recycled to THF, which can be converted to 5,10-
methyleneTHF and 10-formylTHF required for thymidylate and purine synthesis.  The 
enzyme methionine synthase reductase (MTRR) catalyzes the methylation of 
cob(II)alamin back to methyl-cob(III)alamin, restoring the activity of methionine 
synthase (Beaudin and Stover, 2007).  Therefore, the folate pool is cyclic and reflects 
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cellular requirements.   Fifty to eighty percent of homocysteine is remethylated to 
methionine (Bailey and Gregory, 1999).  Liver and muscle are the major storage sites for 
vitamin B12. Enterohepatic reabsorption of cobalamin from the bile protects against 
periods of acute deficiency, as turnover rates are estimated to be low at 0.1% per day.  
Cobolamin Deficiency    
 Vitamin B12 deficiency predisposes an individual to megaloblastic anemia, 
neurological disorders such as Alzheimer’s disease, and bi-polar disorder.  Subacute 
combined degeneration of the spinal chord, which involves deterioration of the myelin 
sheath, is common in upwards of 80% of individuals with clinical B12 deficiency. In 
addition to signs and symptoms, serum concentration of cobalamin and two metabolic 
indices of its metabolism, methyl-malonic acid (> 0.4 µM) and homocysteine (> 13 µM), 
are used to assess vitamin B12 deficiency (Andres et al., 2004).  
 Vitamin B12 deficiency (serum B12 < 150 pM) is believed to exist in roughly 20% 
of the population in industrialized countries (Andres et al., 2004).  Vitamin B12 
deficiency, common in the elderly, results from malabsorption and pernicious anemia. 
Gastric atrophy occurs in over 40% of individuals 80 years of age and may be caused by 
exposure to Helicobacter pylori infection, chronic antacid use, surgery, and antibiotic 
treatments (Andres et al, 2004).  The autoimmune disease, pernicious anemia (Biermer’s 
disease), is a major cause of cobalamin deficiency as it destroys the gastric mucosa, 
decreasing the production of intrinsic factor by the parietal cells of the stomach.  
Cobalamin is bound to haptocorrin (R-factor) in the stomach, forming a complex that 
travels to the small intestine where the change in pH and hydrolysis by pancreatic 
enzymes promote the release of the complex and binding of intrinsic factor, allowing 
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absorption across specialized cells of the ileum (Andres et al., 2004). Without adequate 
cobalamin absorption, methionine synthase cannot adequately remethylate homocysteine. 
If vitamin B12 deficiency exists in the presence of adequate folate, a deleterious 
phenomenon occurs know as the “methyl-trap,” where the folate pool is wastefully 
directed towards the production of 5-methylTHF to remethylate the accumulating 
homocysteine, siphoning the folate pool away from other essential metabolic reactions 
(Beaudin and Stover, 2007). 
Choline and Betaine 
 The enzyme betaine-homocysteine methyltransferase (BHMT) offers an 
alternative, folate-independent remethylation pathway (Lieber and Packer, 2002).  This 
reaction occurs largely in the liver and kidney and is believed to remethylate up to 25% 
of cellular homocysteine in these tissues.  SAM-dependent transmethylation inhibits the 
activity of BHMT, favoring the shunting of homocysteine into the transsulfuration 
pathway. Betaine (trimethylglycine) is derived from the oxidation of choline and forms 
dimethylglycine upon donation of its methyl group to homocysteine.  Choline, a major 
dietary source of methyl groups, is a component of phospholipids (signaling molecule), is 
utilized in the kidney to maintain water balance, and functions as a neurotransmitter 
(acetylcholine) (Zeisel, 1997).  Choline oxidase and betaine aldehyde dehydrogenase 
sequentially oxidize choline to betaine in the mitochondria.  Rodents rely on BHMT for 
the remethylation of homocysteine much more than primates, who rely less on choline 
oxidase (Lieber and Packer, 2002).  Betaine attributes for 0.6-1.6% of total protein in the 
liver of most species and in the Rhesus monkey betaine represents 10% of protein in the 
lens, suggesting functions beyond the remethylation of homocysteine.  The protein is 
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highly conserved, as 88% of the gene and 94% of the amino acid sequence is paralleled 
between pigs and humans (Pajares and Perez-Sala, 2006).  Betaine displays a protective 
role against hyperhomocysteinemia, as an intake of 2-6 g/day can reduce fasting 
homocysteine concentrations by 20% and 50% post methionine load, which folic acid 
alone cannot (Olthof and Verhoef, 2005).  Although a diet rich in betaine and choline 
may adversely affect blood lipid profiles, inadequate intake of betaine and choline 
increases the risk of developing one-carbon metabolism-related disease (Olthof and 
Verhoef, 2005).  
Polymorphism of Methylenetetrahydrofolate Reductase (MTHFR) 
 There are over 10 million single nucleotide polymorphisms (SNPs) in the human 
genome, and many are believed to influence the activity and function of proteins (Stover 
and Caudill, 2008).  A polymorphism arises from an evolutionary response to 
environment (e.g., acute change in diet) and represents a specific form of genetic 
variation within the population.  Examples of positively selected gene SNP(s) include the 
HFE gene, which likely protected populations from iron deficiency in iron-poor regions 
and the SNP upstream of lactase, which allows individuals to continue to consume milk 
throughout life (e.g., nomadic cattle herders) (Stover and Caudill, 2008).  One-carbon 
THF coenzymes are required for multiple unique biochemical pathways within the cell. 
Methylenetetrahydofolate reductase (MTHFR) irreversibly catalyses the conversion of 
5,10-methylenetetrahydrofolate, the primary methyl donor for nucleotide biosynthesis, to 
5-methyltetrahydrofolate the primary cofactor for remethylation of homocysteine to 
methionine.  Inborn errors in the MTHFR gene impair cellular methyl-potential due to 
reduced formation of 5-methylTHF. Individuals born with polymorphisms of MTHFR 
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are at increased risk of developing various pathologies, including colorectal cancer, 
stroke, heart disease, type2 diabetes, and poor reproductive outcomes (Pollex et al., 
2005).  The mutation at base pair position C677 replaces cytosine with thymine, 
ultimately forming valine in place of alanine.  The change in amino acid sequence causes 
thermolability and reduced stability of the enzyme decreasing the activity. Both C667 
homozygous (T/T) and heterozygous (C/T) polymorphisms in MTHFR occur and reduce 
enzyme function 70% and 35%, respectively (Hazra et al., 2009).  
 Polymorphic frequency of the MTHFR gene varies substantially within and across 
racial and ethnic groups.  The homozygous C677TT variant is estimated to exist in 12% 
of both Asian and Caucasian populations, whereas the C677CT heterozygous variant is 
displayed in upwards of 50% of this population (Bailey and Gregory, 1999).  Individuals 
of African descent display lower incidence of both homozygous and heterozygous 
MTHFR gene variance.  The homozygous (T/T) polymorphism increases plasma 
homocysteine concentrations and the predicted increase is strongly correlated to observed 
risk of developing a stroke (Casas et al., 2005). MTHFR polymorphisms are strongly 
associated with the development of head and neck carcinoma (Reljic et al., 2007).  
Therefore, chronic disease related to one-carbon metabolism may initiate not only from 
dietary insufficiency but also underlying genetic predispositions (Suzuki et al., 2008). 
 The C677 homozygous (T/T) and heterozygous (C/T) polymorphisms affect 
cellular folate homeostasis by altering the complex flux of one-carbon folate derivatives 
(Wilcken and Wilcken, 1998).  Wild-type MTHFR (C/C) erythrocyte folates exist 
primarily as 5-methylTHF polyglutamates, whereas in C677TT variants erythrocyte 
folates include up to 22% formyl-THF polyglutamates, a reflection of reduced enzyme 
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function (Bailey and Gregory, 1999).  Previous research indicates conflicting outcomes 
within MTHFR variants including lower fasting plasma homocysteine concentrations in 
C677TT homozygotes and both positive and negative effects on erythrocyte folate 
concentration.  Although the C677TT gene variant is believed to be the most potent of all 
MTHFR polymorphisms, supplementation with folic acid reduces plasma homocysteine 
more effectively in this variant when compared with heterozygous (C/T) or wild-type 
(C/C) genotypes (Bailey and Gregory, 1999).  Therefore, exacerbation of plasma 
homocysteine concentrations and alterations in cellular methyl-potential noted in 
C677TT variants is highly dependent upon folate status. Optimizing folate intake may 
stabilize the thermolability of the mutant (T/T) enzyme, suggesting a higher folate 
requirement in these individuals (Ilhan et al., 2007). MTHFR (T/T) variants consuming 
adequate folate or folic acid supplements are less likely to develop colorectal cancer, 
whereas these protective effects are negated in subjects with low blood folate levels 
(Wilcken and Wilken, 1998).  Vitamin B12 deficiency is strongly associated with elevated 
plasma homocysteine in MTHFR C677TT gene carriers (Angelo et al., 2000).    
  A second common polymorphism in the MTHFR enzyme occurs at base pair 
position 1298, where adenine is substituted with cytosine, ultimately forming alanine in 
place of glutamate.  Approximately 10% of individuals are believed to exhibit this 
polymorphism (Weisberg et al., 1998).  The substitution at base pair 1298 is not believed 
to increase plasma homocysteine concentrations. In fact, homozygous (C/C) variants may 
exhibit lower fasting plasma homocysteine. Nevertheless, isolated lymphocytes from 
individuals with the 1298CC polymorphism have a 40% reduction of MTHFR activity 
(Weisberg et al, 1998).   The 1298CC mutation is believed to affect MTHFR signaling 
 
   
 
22 
through SAM, whereas the C677C/T and T/T variants modulate the catalytic ability the 
enzyme itself.  Collectively, T/T and C/C polymorphisms steer one-carbon moieties, 
directed by folate derivatives to either methionine metabolism or DNA methylation, as 
expressed by the ability to form 5-methylTHF (Figure 1.3).   
 
Figure 1.3.  Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and 
methylation potential (Taken from Blom et al., 2006). 
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Transsulfuration and Disease 
 The enzyme cystathionine β-synthase (CBS) metabolizes homocysteine to 
cystathionine, which is converted by cystathionine γ-lyase (CGL) to cysteine, ammonia, 
and α-ketoglutarate in a process called transsulfuration.  Transsulfuration occurs 
primarily in the liver but not in all tissues (Finkelstein et al., 1971).  Both CBS and CGL 
require pyridoxal 5-phosphate (B6) as cofactors.  Approximately 50% of homocysteine 
derived from cellular methionine is metabolized via transsulfuration. In addition to 
cysteine, other molecules including, taurine, glutathione, and pyruvate, may be formed 
via transsulfuration.  The production of glutathione is dependent upon cellular cysteine 
availability (Cho et al., 1984).   Cysteine is converted to γ-glutamylcysteine and then 
glutathione (γ-glutamylcysteinylglycine) through consecutive energy-dependent reactions 
with glutamate and glycine (Lieber and Packer, 2002).  
 Glutathione is also an endogenous source of cysteine and functions as a source of 
sulfhydryl, as an amino acid transport molecule, a cosubstrate in drug metabolism and 
detoxification, and as a major redox molecule within the cell (Cho et al., 1984).  Cysteine 
deficiency, occurring protein energy malnutrition in premature infants, can deplete 
glutathione stores in the liver.  Glutathione protects cellular membranes from lipid 
peroxide damage.  Therefore, cysteine depletion associated with starvation or strict 
adherence to parenteral nutrition can disrupt cellular redox homeostasis (Cho et al., 
1984).   
 Classic homocystinuria is a consequence of at least one mutation in the gene 
coding for the enzyme cystathionine β-synthase (CBS) and can perturb the 
transsulfuration pathway that catabolizes the carbon skeleton of homocysteine.  In 
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addition to elevated plasma homocysteine concentrations, CBS variants display ectopic 
lentis, myopia, elongated limbs, and impaired cognitive development (Yap, 2005).  If left 
untreated, advanced morbidities including scoliosis, osteoporosis, seizers, mental 
retardation, and thromboembolism can develop in early adulthood (Picker and Levy, 
2004).  Newborn and clinical screening likely underestimates the prevalence of CBS 
deficiency, which is of particular concern in populations exhibiting nutrient deficiencies, 
namely vitamin B6, folate, and vitamin B12 (Yap, 2005).    
 Prior to the development of advanced biochemical techniques, the term 
homocystinuria described severely elevated urine homocysteine concentrations due to 
unknown errors in the enzymes regulating methionine metabolism (Mudd et al., 2000). 
Normal urinary excretion of homocysteine is in the range of 3.5 to 9.5 µmol/L and is 
considered low with an average of 6 µmol excreted per 24-hour period (Refsum et al., 
1985).  Therefore, homocystinuria currently relates largely to polymorphisms of CBS, 
which significantly elevates urinary homocysteine. In the United States, the reported 
incidence of homocystinuria due to CBS deficiency is 1:100,000.  Over 18% of 
individuals diagnosed with CBS enzyme deficiency will die by 30 years of age due to 
cardiovascular disease (Mudd et al., 2000).  The two major recessive, autosomal CBS 
polymorphisms are the I278T and G307S missense mutations found on exon 8 (Yap, 
2005).  Polymorphism I278T is the major disease causing mutation, representing 29% 
and 18% of mutant alleles in the United Kingdom and United States, respectively. The 
G307S mutation is most common in individuals of Irish decent.  Over 70% of CBS 
mutations in the Irish population are located at G307S.  The treatment regimen for CBS 
functional variance includes supplementation with folic acid, vitamin B12, vitamin B6, and 
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betaine, and in certain circumstances a protein restricted diet (e.g., methionine restricted, 
cysteine supplemented diet) (Picker and Levy, 2004).   
Epigenetics 
 Epigenetics is the study of heritable changes in gene expression not caused by 
alterations in DNA sequence (G-C-A-T) but rather by superimposed additions to the 
underlying sequence.  Epi,” Greek for “above,” describes the addition of a molecule to 
DNA or DNA-complex protein such as a histone or DNA that modifies transcription and 
ultimately the phenotype of a particular cell, tissue, and organism.  Epigenetic 
mechanisms include but are not limited to nucleosome remodeling, DNA methylation, 
prion inheritance, nucleosome modification, chromosome remodeling, gene imprinting, 
micro RNA, and histone acetylation or ribosylation.    
 Environmental factors including nutritional status and exposure to stress, toxins, 
and infectious agents are believed to continually modify the epigenome (Stover and 
Caudill, 2008).  Although not all epigenetic imprints are permanent, inheritance by 
subsequent generations may influence the ultimate susceptibility to numerous diseases 
depending upon the specific characteristics of the modification.  DNA methylation is an 
epigenetic mechanism that is highly influenced by environment, particularly B-vitamin 
status as folate derivatives not only function in nucleotide synthesis but also in DNA 
methyltransferase reactions, which regulate gene expression (Ross, 2003).  DNA 
methylation involves the addition of a methyl group to the 5’ carbon of the pyrimidine 
nucleus of cytosine within cytosine-guanine regions of DNA.  Roughly 80% of the CpG 
dinucleotide regions of the genome are normally methylated, which serves to suppress 
transcription after the formation of new DNA strands (Strain et al., 2004).  It is estimated 
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that approximately 30% of the genome is regulated through DNA methylation (Beaudin 
and Stover, 2007).  Methylation impedes transcription and stabilizes cellular expression 
(Figure 1.4).  In doing so, proliferated cells maintain tissue-specific function throughout 
successive mitotic events.  Methylation can also occur at normally unmethylated, 
clustered DNA regions known as CpG islands that exist at the promoter region of some 
genes.    
DNA Methylation and Disease 
 Global hypomethylation or hypermethylation of regulatory regions dictates 
whether a gene is active or inactive and homeostatic deviations can influence disease 
development.  DNA methylation modifies gene expression and cellular function by 
modifying transposable elements, the promoter regions of housekeeping genes, and the 
regulatory regions of imprinted genes (Dolinoy et al., 2006).  The influence of 
environment on DNA methylation may be most crucial during key events along the life 
span, including gestation, lactation, and puberty due to fetal programming, high rates of 
cell division, and hormonal flux (Dolinoy et al., 2006).  Epigenetic events are believed to 
occur in utero and can be modified by maternal diet (Ross, 2003).  Pregnant agouti mice 
(YS/WffC3Hf/Nctr-Avy and VY/WffC3Hf/Nctr- Avy) were fed either a methyl deficient or 
adequate diet (i.e., methionine, betaine, choline, vitamin B12, and folate).  The long 
terminal repeat of the agouti gene is hypomethylated in the offspring of mothers fed a 
methyl-deficient diet and the offspring exhibit varying degrees of yellow fur, adiposity, 
and diseases, including cancer.  Providing a diet rich in methyl groups prevents 
hypomethylation of the agouti gene and the offspring are born with and maintain the wild 
type, lean/agouti (e.g., brown coat color) phenotype.        
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 Figure 1.4.  DNA methylation and inhibition of transcription (Taken from Januchowski 
et al., 2004; Signal and Ginder, 1999) 
 Abnormal DNA methylation patterns are common in most cancers, including 
lung, prostate, breast, and colon cancers.  The DNA methyltransferase enzymes catalyze 
the SAM-dependent methylation of DNA, forming SAH and 5-methylcytosine.  The 
enzyme Dnmt-1 is responsible for maintaining normal DNA methylation during cellular 
division (mitosis), whereas Dnmt-3a and 3b are responsible for de novo DNA 
methylation, an important epigenetic event (Jeltsch, 2006). In addition to global 
hypomethylation, which causes chromosomal instability and site-specific 
hypermethylation, which inactivates DNA repair and cell regulatory mechanisms, 
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changes in Dnmt activity are also associated with carcinogenesis (Momparler and 
Bovenzi, 2000).  The increase in Dnmt activity may be in response to fluctuations in 
cellular SAM homeostasis during methyl deficiency (i.e., cofactors).  In terms of DNA 
methylation, cancer can be described as a general loss of methyl groups at CpG islands 
thereby promoting the activation of normally inactivated genes that influence cell growth 
(Momparler and Bovenzi, 2000).   
 Feeding animals a diet absent of “methyl groups” (e.g., choline ad methionine) 
causes progressive loss of histone H3 lysine-9 trimethylation, H4 lysine-20 
trimethylation, H3 lysine-9 acetylation, and H4 lysine-16 acetylation (Pogribny et al., 
2007).  Histones are highly conserved proteins that organize and compact DNA into 
structural units called nucleosomes. Histones contain a globular carboxy-terminal end 
that makes up its core structure and a flexible amino-terminal tail that attaches to 
neighboring histones, forming a larger, more complex structure (Cheung and Lau, 2005).  
These amino-terminal tails can be modified posttranslationally by phosphorylation, 
ubiquitination, ribosylation, acetylation, and methylation.  Histone methyltransferase 
activity is downregulated during methyl-deficiency, changing not only the nature of the 
nucleosome but signaling within the cell including upregulation of cell cycle regulatory 
genes (e.g., tumor-suppressor family proteins) (Pogribny et al., 2007).   
 Animals fed a methyl cofactor-deficient diet display increased expression of 
oncogenes including c-myc and c-fos (Ross, 2003).  The regulatory element of the tumor 
suppressor gene, p53, which regulates the cell cycle (i.e., apoptosis, senescence, and 
repair), upon stress (e.g., UV damage, DNA adducts) is hypomethylated in early 
preneoplastic nodules.  However, its expression is diminished in mature tumors through 
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hypermethylation of its promoter region, highlighting one of many complex occurrences 
during metastasis (Ross, 2003).   
 DNA methylation status may also be an important factor in certain autoimmune 
diseases, namely systemic lupus erythematosus (SLE) (Januchowski et al., 2004).  
Autoreative T cells (Th2-CD4+) exhibit hypomethylated DNA and reduced Dnmt-1 
methyltransferase activity, in turn over-expressing costimulatory molecules that 
propagate autoantigen formation, inflammation, and activation of other effector cells (i.e., 
B cells, NK cells, Th1/CD8+ cells) and their products (i.e., antibodies, complement, 
chemokines, and cytokines) against self-antigens (Palmer, 2003; Pan and Sawalha, 2008).  
The initiation of lupus pathogenesis is undefined and exposure to certain drugs, such as 
blood pressure medications may represent one possibility, as they can interfere with 
cellular signaling (e.g., MAPK/ERK) changing the activity of Dnmt(s) (Lu et al., 2005; 
Sawalha et al., 2008).  The drug 5-azacytidine, a Dnmt-1 inhibitor, can induce 
autoreactivity in T cells and produce lupus-like symptoms in mice (Quddus et al., 1993).  
B cells exposed to high concentrations of single-stranded hypomethylated (CpG)n-DNA, 
a highly conserved pathogen associated molecular pattern (PAMP) recognized by TLR-9, 
form immune complexes and stimulate the formation of autoreactive dendritic cells 
instead of non-reactive follicular B cells (Lenert, 2006).  Therefore, environmental 
exposure to chemicals and pathogens represent two important disease-related epigenetic 
phenomena.    
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Genistein 
 A balanced diet low in lipids rich in saturated fatty acids and high in fruit, 
vegetable, and grain content is associated with a decreased risk of developing chronic 
disease including cardiovascular disease and certain cancers.  In addition to vitamins, 
minerals and fiber, plant-based foodstuffs contain numerous bioactive compounds that 
also contribute largely to their associated health benefits.  The isoflavanoids are a group 
of such constituents found at high concentrations in the diet of Asians, a population 
exhibiting a lower prevalence of chronic disease compared to those living in Western 
countries (Sakai and Kogiso, 2008).     
 Certain phytochemicals, namely phytoestrogens, elicit beneficial health effects in 
numerous animal and human studies including treatment and prevention of 
cardiovascular disease, cancer, hyperlipidemia, osteoporosis, and enhancement of 
immune function (Sakai and Kogiso, 2008).  Isoflavones are the most abundant dietary 
source of phytoestrogens, a group of molecules similar in structure to 17β-estradiol 
(Figure 1.5).   
 The most common food sources of isoflavones are soybeans and soy-containing 
foodstuffs (e.g., tofu, soy milk, and soy sauce).  In addition to soybean, other legumes, 
lentils, peas, grains, and clover contain isoflavones but at a lower concentration.  
Geographic agronomic variation and food processing and storage methods vary the 
isoflavone content of foods (Sakai and Kogiso, 2008).  Daidzein (4’,7-
dihydroxyisoflavone) and genistein (4’,5,7-trihydroxyisoflavone) represent the two most 
abundant forms of isoflavones found in soy.  Both molecules have been studied 
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extensively in the context of hormone-related disease including treatment and prevention 
of estrogen-responsive cancers, post-menopausal therapies, and cardiovascular 
pathogenesis (Cappelletti et al., 2006).  
 
 
Figure 1.5.  Receptor binding domain similarity of genistein and 17β-estradiol (Taken 
from Wang et al., 1996) 
 The protective effect of estrogens in prevention of coronary artery disease is 
diminished with the onset of menopause in women.  However, the use of hormone 
replacement therapy (HRT) to prevent bone-loss and reduce the side affects of 
menopause may promote the risk of breast cancer, venous thrombosis, ovarian cancer, 
and stroke.  It is recommended that HRT is administered at the lowest dosage and 
shortest duration required to alleviate menopausal symptoms (Marini et al., 2009).  
Estrogens influence cellular growth and differentiation and function through estrogen 
receptors, which are ligand-activated transcription factors (Katzenellenbogen et al., 
2000).   
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Genistein and Health   
  In 1999, the Food and Drug Administration (FDA) began to label soy products as 
heart healthy (Sacks et al., 2006).  In 2006, the American Heart Association (AHA) 
determined, based on previous research findings, that both soy isoflavones and protein do 
not provide significant protection against cardiovascular risk factors.  
 Early animal studies indicated that soy protein substituted for animal protein 
could reduce LDL cholesterol and have beneficial effects on triacylglycerol profile.  
However, when applied to a vegetarian diet, no additional cholesterol-lowering effect 
was determined (Sacks et al., 2006).  Data stemming from the original work, including 
complete protein replacement by soy in an omnivore diet, was confounded due to 
additional, unaccounted changes in food lipid profiles (Marini et al., 2009).  The AHA 
meta-analysis argues that dietary soy isoflavones have minimal benefits on HDL-
cholesterol, triacylglycerol profile, blood pressure, vasomotor menopause symptoms, and 
slowing osteoporosis (Sacks et al., 2006).  Additionally, the estrogenic actions of 
genistein may pose safety concerns when applied as a treatment of breast, endometrial, 
and prostate cancer (Sacks et al., 2006).   
 In plants, isoflavones are associated with proteins as bound glycosides 
(conjugated glycones).  Intestinal microflora can ferment these compounds, removing the 
associated sugar residue, forming the aglycones genistein and daidzein from genistin and 
daizdin, the most abundant forms of isoflavones in soy products. Free genistein and 
daidzein are absorbed across the intestinal lumen epithelium efficiently as well as in the 
stomach (Marinin et al., 2009).  In the colon, bacteria can further metabolize daidzein to 
equol and O-demethylangolesin and genistein to p-ethyl phenol.  Once absorbed, these 
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compounds are not subject to further metabolism and represent collectively the most 
abundant circulating and excreted forms of isoflavanoids.  Typically, 250-350 mg/kg diet 
genistein is administered to rodents to model intake by individuals regularly consuming 
soy foodstuffs without supplementation.  Such a diet, common in Asian and Western 
vegetarian populations, contains 1.4 mg/kg body weight genistein (Coward et al. 1993).  
Infants consuming soy-based formulas can achieve intakes over 5 mg/kg body weight 
genistein daily (Setchell, et al., 1997).  Women who regularly consume soy foodstuffs 
exhibit plasma genistein concentrations of 0.7-6.0 µmol/L (Fang et al., 2007).  
Genistein and Estrogens 
 The structural similarity of genistein to 17β-estradiol suggests its ability to 
mediate cellular processes in a hormone-like fashion.  Endogenous estrogens can regulate 
transcriptional activation and repression of both estrogen receptor alpha (ER-α) and 
estrogen receptor beta (ER-β) (Cappelletti et al., 2006).  These receptors differ in the 
amino acid profiles of their N-terminal domains (82%) and hormone-binding domains 
(44%) (Katzenellenbogen et al., 2000).  These differences explain in part the varying 
affinity of ligands between receptor subtypes, and the paradoxical (e.g., agonist versus 
antagonist) effects of binding ligands (Katzenellenbogen et al., 2000).  Despite its similar 
structure, the binding affinity of genistein to ER-α is 0.5 to 1% of that of 17β-estradiol 
(Ye et al., 2009).  However, genistein binds ER-β at even higher affinity than 17β-
estradiol, functioning as a selective estrogen receptor modulator (SERM) (Ye et al., 
2009).  In this role, genistein selectively serves as both an estrogen receptor agonist and 
antagonist depending upon the tissue of interest and dosage (Dolinoy et al., 2006; Price 
and Fenwick, 1985). 
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Estrogen and Disease  
 The atheroprotective effect of estradiol is mediated through endothelial ER-α by 
cyclooxygenase-2, direct inhibition of lipid deposition on endothelial cells, rather than 
changes in blood lipid profile (Billon-Gales et al., 2009).  In addition, estradiol may 
mediate the adaptive immune response away from the production of proinflammatory 
cytokines (Elhage et al., 2005).  Conversely, the protective role of genistein in estrogen-
responsive cancers is believed to be consequence of its structural binding to ER-β.  Both 
estrogen dependent and independent mechanisms have been suggested for the positive 
and negative immune modulatory effects of genistein.  Inhibition of estrogen signaling 
pathways, in lymphocytes and macrophages, reduces the effect of genistein on these cells 
(Sakai and Kogiso, 2008).  Upon binding to ER-β, genistein recruits coregulatory 
proteins to the receptor and forms an AF-2 helix, which inhibits estrogen agonist activity 
and thus represents its antagonist regulation (Cappelletti et al., 2006).  Cappelletti et al. 
(2006) determined that genistein, through the action of ER-β, inhibits estrogen-related 
cell growth but does not inhibit estrogen-regulated transcription (Cappelletti et al., 2006).  
 Genistein also has been shown to interact with other steroid nuclear receptors 
including the vitamin D receptor (VDR).  Genistein can upregulate both the expression 
and abundance of VDR in estrogen-positive breast cancer cell lines (Wietzke and Welsh 
et al., 2003).  The tissue-specific molecular actions of genistein are not completely 
understood.  Compared with 17β-estradiol, genistein exhibits paradoxical effects of other 
synthetic estrogen molecules developed for health interventions.     
 The structure of genistein and daidzein is also similar to the synthetic estrogens 
diethylstilbestrol (DES) and hexestrol, respectively, altering the same 179 genes in the 
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immature mouse uterus causing a parallel uterotrophic response (Moggs et al., 2004).  
These potent non-steroidal anabolic compounds have been used widely to regulate sexual 
maturation, growth in livestock, and for treatment of estrogen-responsive diseases (e.g., 
uterine fibromyoma and sterility).  However, since their discovery in the first half of the 
20th century, safety concerns have limited their widespread application (Verloop and 
Leeuwen, 2010).  Women prescribed DES between 1938 and 1971 during pregnancy for 
miscarriage prevention are 30% more likely to develop breast cancer compared to the 
normal population.  DES “sons” are at increased risk to develop non-cancerous 
epididymal cysts and “daughters” bear the greatest detriment, including clear cell 
adenocarcinoma, reproductive tract defects (e.g., T-shaped uterus), and pregnancy 
complications including ectopic implantation, preterm delivery, and sterility.  Recent 
literature has indicated that third generation DES individuals may also be at risk for 
reproductive defects (Titus-Ernstoff et al., 2008).  
 Aromatase (CYP19), a cytochrome P450 enzyme, catalyzes the final rate-limiting 
step in the synthesis of estrogen from cholesterol.  In the endoplasmic reticulum, 
aromatase performs three hydroxylation reactions of the 19-methyl group of androgen 
molecules derived from cholesterol, removing the methyl-group as formate and 
transforming the left-hand A-ring structure to an aromatic state.  Exogenous estrogen 
administration or perturbations in endogenous estrogen synthesis, including 
polymorphisms in the CYP19 gene have been shown to induce and accelerate mammary 
carcinogenesis in mice (Yoshidome et al., 2000).   
 Estrogen promotes cellular proliferation via signaling and involvement in cell 
cycle regulation, including modulation of various proteins and transcription factors 
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related to growth and apoptosis.  Ye and colleagues (2009) determined that treatment 
with 10 µmol/L genistein was able to increase aromatase activity and expression in 
HepG2 cells through phosphorylation of the protein kinases (PKCs), extracellular 
signaling kinase (ERK), p38, and mitogen activated protein kinase (MAPK), in turn 
promoting the DNA binding of CREB to CYP19.  Perturbations in estrogen homeostasis 
mediated by aromatase are associated with the development of hepatocellular carcinoma 
(HCC), indicating that genistein administered at significant quantities may promote the 
survival and growth of estrogen responsive neoplastic cells.   
Genistein and Disease 
 An achievable, single intake of genistein (30-60 mg) produces a blood 
concentration of roughly 1 µmol/L, assuming there is minimal microbial degradation in 
the small intestine and variable absorption of 13-46% based on luminal perfusion data 
and human research accounting for variation in gut-flora (Andlauer et al.2000). 
Circulating concentrations of genistein exceeding 4 µmol/L can produce estrogenic 
effects in laboratory animals (Penza et al., 2007).  Genistein concentrations in the blood 
drop significantly within 12-24 hours after ingestion and are found to be localized largely 
in the liver and reproductive tissues, including the uterus, testes, vagina, prostate, and 
prostatic fluid (Penza et al., 2007).  Genistein metabolism and hepatic biotransformation 
is similar between rats and humans, which form glucuronide conjugates upon 
metabolism.  The estrogenicity of the glucuronide conjugates is less potent than that of 
genistein.  However, the activity of these products is not completely understood 
(Bursztyka et al., 2008).   
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 Genistein also functions broadly as a tyrosine-kinase inhibitor of cellular growth 
factors including pathways of epithelial growth factor receptor (EGFR) and the 
oncogenes pp60v-src and pp110gag (Akiyama et al., 1987).  Regulation of the EGFR is 
mediated through competitive binding in multiple places of the reaction pathway and not 
solely as a competitive binder of phosphate (e.g., ATP-binding sites) (Akiyama et al., 
1987).  Genistein has been shown to inhibit the growth of estrogen-responsive LNCaP by 
inducing G0-G1 phase arrest through upregulation of the tumor suppressor gene, cyclin 
p21.  Genistein also inhibits the G2-M phase of cellular replication in breast, gastric, lung, 
and human melanoma cells lines through the action of CDK inhibitors p21WAFI and 
cyclin B1, which govern DNA replication (Majid et al., 2008).   
 Genistein can induce apoptosis in cancer cells by upregulating BRCA1 and the 
tumor suppressor gene p16.  The promoter regions of these genes are normally 
hypomethylated in cancer cell lines.  Genistein treatment does not methylate the CpG 
promoter regions of these regulatory genes.  Therefore, the anti-cancer activity of 
genistein may not be related to changes in the DNA-methylation patterns.  However, 
genistein was found to increase histone (H3 and H4) acetylation in a dose-response 
fashion near the transcription site of the regulatory genes.  Genistein was found to 
upregulates histone acetyltransferases (HAT) and induces chromatin remodeling, which 
in turn may represent a component of its anti-cancer activity (Majid et al., 2008).  
However, genistein has been shown to alter prostate DNA methylation patterns in mice 
but not in liver tissue, regardless if the animals were fed control diet weeks before or after 
genistein supplementation, indicating that changes in estrogen-responsive tissue DNA 
methylation may be stably altered (Day et al., 2002).  In this regard, genistein has been 
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shown to reduce the risk of cancer in female rats whose mothers were fed genistein.  
However, post-natal supplementation did not provide a protective effect (Warri et al., 
2008).        
 The proposed anti-atherogenic activity of genistein is similar to that of 
endogenous estradiol in that it may lower plasma homocysteine concentrations, prevent 
LDL oxidation, improve vascular tone, and decrease the production of inflammatory 
cytokines, reactive nitrogen species and cell-adhesion molecules (Fuchs et al., 2005).  
Genistein treatment (2.5 µmol/L) has been shown to prevent homocysteine-induced (25 
µmol/L) cytoskeleton protein changes in endothelial cells, inhibiting apoptosis, which 
was determined by measurement of DNA-fragmentation and chromatin condensation 
(Fuchs et al., 2005).   
 Genistein has been shown to decrease the activity of all three DNA 
methyltransferase (e.g., Dnmt-1, 3a, and 3b) in both benign and malignant breast cancer 
cells, down-regulating telomerase activity by inhibiting the transcription of the human 
telomerase reverse transcriptase promoter (hTERT), causing cellular arrest and apoptosis 
(Li et al., 2009).  Genistein has been shown to induce permanent alterations in the 
epigenome by using the agouti mouse model. Administration of genistein at 250 mg/kg 
diet to pregnant female agouti mice shifted the offspring’s coat color toward pseudo-
agouti and prevented adiposity.  Genistein was found to hypermethylate CpG sites 
upstream of the of the promoter region of the agouti gene, reducing yellow phaeomelanin 
production and protecting against adult-onset adiposity (Dolinoy et al., 2006). These 
changes persisted into adulthood and the alterations in DNA methylation were 
independent of one-carbon metabolism (Dolinoy et al., 2006).  These results demonstrate 
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the effects of environmental factors on epigenetic regulation during prenatal and early 
postnatal development and also suggest that folate status is very important when 
consuming genistein, as potentially additive effects may occur in relation to DNA 
methylation altering cellular function and ultimate disease susceptibility.     
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CHAPTER 2. GENISTEIN MEDIATES PERTURBATIONS IN ONE-CARBON 
METABOLISM DURING DIET-INDUCED FOLATE DEFICIENCY 
Abstract 
 Populations consuming isoflavone-rich diets exhibit lower prevalence of heart 
disease and estrogen-responsive cancers.  Genistein, a17β-estradiol-like isoflavone, has 
been shown to modify the fetal epigenome in utero in the agouti mouse model and 
modulate DNA methylation patterns in estrogen-responsive tissues. Genistein also 
exhibits antiproliferative action in cancerous cells via suppression of S-
adenosylmethionine-dependent DNA methyltransferases, leading to site-specific 
hypomethylation in cell cycle regulatory genes.  However, it is not known if genistein 
modulates one-carbon metabolism, a process that when disrupted leads to dysregulation 
of the epigenome.  The objective of these studies was to characterize the metabolic 
actions of genistein related to one-carbon metabolism, including the ability of genistein to 
reduce plasma homocysteine, and alter transmethylation, remethylation, and 
transsulfuration enzymes perturbed by folate deficiency. Male Sprague Dawley rats were 
fed either a folate adequate (Ctrl) or deficient diet (FD) with or without genistein (300 
mg/kg diet). In the first study, rats were fed an FD diet for a total of 38 d, and were 
administered either genistein (300 mg/kg diet) or creatine monohydrate (4 g/kg diet) 
during the last 10 d of the study period. In the second study, rats were administered 
genistein for 24 of the 38 total d. In the third study, rats were acclimated for 5 d on a Ctrl 
diet prior to feeding a FD diet for 59 d with simultaneous genistein administration. 
Moderate folate deficiency did not alter enzyme function or genomic DNA methylation 
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patterns.  However, the associated hyperhomocysteinemia was attenuated in all three 
studies by genistein.  Genistein administration had no effect on plasma homocysteine 
concentrations in Ctrl fed rats.  Genistein administration was not found to alter the 
activity or expression of hepatic enzymes regulating one-carbon metabolism or produce 
alterations in genomic DNA methylation patterns.  Genistein may be acting on estrogen-
responsive tissues, altering homocysteine metabolism. Genistein could also be mediating 
one-carbon metabolism independently of folate via an unknown mechanism. Future 
research is required to better understand the actions of genistein related to its ability to 
modulate homocysteine metabolism.             
Introduction 
 Hyperhomocysteinemia is associated with various pathological conditions 
including cardiovascular disease, neural tube defects, neurodegenerative diseases, and 
cancer (Cattaneo, 1999).  Homocysteine, a non-protein amino acid, is an intermediate in 
methyl group metabolism. S-adenosylmethionine (SAM), the major methyl group donor 
for all organisms, forms S-adenosylhomocysteine and ultimately homocysteine.  Upon 
formation, Homocysteine undergoes remethylation to generate methionine by both folate-
dependent and independent routes or undergoes catabolism to cysteine via the 
transsulfuration pathway (Figure 2.1) (Wagner, 1995).  Reduced intake of folic acid, B12, 
and pyridoxine (B6) contribute to elevated plasma Homocysteine, perturb cellular methyl 
potential, and represent biomarkers for epigenetic perturbations (Fux et al., 2005).  In 
addition, missense mutations in the 5,10- methylenetetrahydrofolate reductase (MTHFR) 
gene (C677-position polymorphism) causes thermolability and attenuated activity of 
MTHFR, an enzyme responsible for the formation of 5-methyl-THF, which remethylates 
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Homocysteine back to methionine via methionine synthase (MS) (Ilhan et al., 2008).  
 Polymorphism in genes regulating folate metabolism, such as MTHFR, exist in 
upwards of 15% of the population and pose substantial risk for certain individuals, 
namely women of child-bearing age (Bailey and Gregory, 1999).  The SAM-dependent 
enzymes guanidinoacetate N-methyltransferase (GAMT) and phosphatidylethanolamine 
N-methyltransferase (PEMT) form creatine and phosphatidylcholine respectively, 
consuming upwards of 80% of the tightly regulated methyl groups (Figure 2.1).  
Research conducted by Brosnan and colleagues has determined that supplementation with 
creatine monohydrate (4 g/kg diet) significantly reduces plasma homocysteine 
concentrations by 50%, while administration of its precursor, guanidinoacetate, inversely 
increased homocysteine concentrations by 25% (Stead et al., 2001).  The remaining 
SAM-derived methyl donations are allocated largely to DNA methylation, an epigenetic 
process influenced by the dietary isoflavone genistein (Day et al., 2002). DNA 
methyltransferase (DNMT) 1, 3a, and 3b, which govern maintenance and de novo DNA 
methylation, respectively, are potential targets for cancer therapy.  
 Epigenetic regulation includes cellular changes that modify transcription, 
translation, and posttranslational events without alterations of the underlying base 
sequence of DNA. Recently, epigenetic regulatory mechanisms, including DNA 
methylation, have become increasingly implicated in various diseases (Oommen et al., 
2005).  Genistein (4’, 5,7-trihydroxyisoflavone), a 17β-estradiol-like isoflavone, has been 
shown to maintain normal methyl group metabolism in the agouti mouse model fed a 
methyl-deficient diet.  Maternal genistein supplementation during gestation produces 
pseudo-agouti offspring via hypermethylation and suppression of regions upstream of the 
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agouti gene (Dolinoy et al., 2006).  In the human diet, genistein is largely consumed via 
soy-based foodstuffs or supplements used as therapy for menopausal.  Although dietary 
genistein does not directly provide a methyl group for metabolism, it may modulate the 
one-carbon pool and influence DNA methylation particularly in estrogen-responsive 
tissues (Fang et al., 2007).  Genistein, as a dietary agent, may have the greatest effect on 
cellular events during embryonic development (gestation), puberty, and lactation, when 
hormones such as estrogens influence maturation (Cappelletti et al., 2006).  
 Genistein interacts with a number of cellular receptors, including the estrogen β-
receptor, which it binds at an even higher affinity than endogenous 17β-estradiol, 
resulting in both activating and inhibitory regulation within the cell (Cappelletti et al., 
2006).  Recently, genistein was shown to down-regulate telomerase activity in cancer 
cells, inducing apoptosis.  Genistein can induce repression of telomerase through 
hypomethylation of the hTERT promoter in a similar fashion to the DNMT-1 inhibitor 5-
2’-deoxycytidine in breast cancer cells (Li et al., 2009).  The extent genistein directly 
influences methyl group and SAM/Homocysteine metabolism is not known (Figure 2.1).  
 In the present study, the effects of supplemental genistein on elevated plasma 
Homocysteine, during diet-induced, moderate folate deficiency were examined.  The 
supplement dose was chosen to mimic intakes by individuals consuming a diet rich in 
soy-based products (e.g., tofu and soy milk).  By using a folate restriction model, our 
study aimed to represent portions of the population with reduced folate absorption, 
intake, or altered metabolism (e.g., geriatric populations or MTHFR variants) (Wilcken 
and Wilcken, 1998).  Previous research investigating the effect of genistein on 
Homocysteine metabolism is limited to the study of its role as an antioxidant, although 
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there are reports regarding its use in the prevention of Homocysteine-related pathologies, 
including cardiovascular disease and cancer (Fuchs et al., 2005).  By examining the 
specific interaction of genistein in one-carbon metabolism in vivo we can begin to 
understand its global actions during chronic disease.  
Experimental Procedures 
Animals and Diets 
Experimental Design 1 
 Animal care and experiments were conducted in accordance with the Iowa State 
University, Institutional Animal Care and Use Committee (IACUC), Laboratory 
Resource Guidelines.  Male Sprague Dawley rats (Harlan Teklad, Sprague Dawley, 
Indianapolis, IN) were assigned randomly to individual plastic cages and placed in a 
room with a 12-h light:dark cycle.  Rats were allowed access to food and water ad lib.  
Rats were obtained at 3-4 weeks of age (50-74g) and fed for 28 d on an AIN-93 (Harlan 
Teklad, Indianapolis, IN) control diet containing, 10% vitamin free casein, 0.3% L-
methionine, 40.2% corn starch, 39.3 % dextrose, 5% corn oil, 4% mineral mix (AIN-
93G-MX), 1% vitamin mix (AIN-93-VX), and 2% choline bitartrate (1.5 mol/L) to 
promote growth.  Rats were assigned to 6 groups (6 rats per group) fed the following 
diets: control (2 ppm folate), deficient (0 ppm folate) during the 28-d period. Parallel 
diets supplemented with 300mg/kg diet 99%+ purity genistein (Indofine Chemical 
Company, Hillsborough, NJ; G-103) or 4 g/kg diet creatine monohydrate (Sigma Aldrich, 
St Louis, MO) were fed for an additional 10 d.  Cornstarch (0.3 g and 4.0 g) was removed 
from the diet and replaced with genistein or creatine.     
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Experimental Design 2 
 Male Sprague Dawley rats (Harlan Teklad, Sprague Dawley, Indianapolis, IN) 
were assigned randomly to individual plastic cages and placed in a room with a 12-h 
light:dark cycle.  Rats were allowed access to food and water ad lib.  Rats were obtained 
at 3-4 wk of age (50-74g) and placed in a diet containing, 10% vitamin free casein, 0.3% 
L-methionine, 40.2% corn starch, 39.3 % dextrose, 5% corn oil, 4% mineral mix (AIN-
93G-MX), 1% vitamin mix (AIN-93-VX), and 2% choline bitartrate (1.5 mol/L) with 
either adequate folate (2 ppm folate) or folate-deficient vitamin mix (0 ppm folate) for 14 
d prior to supplementation with 300 mg/kg diet 99%+ purity genistein (Indofine 
Chemical Company, Hillsborough, NJ) for an additional 24 d. Cornstarch (0.3 g) was 
removed from the diet and replaced with genistein.        
Experimental Design 3  
 Male Sprague Dawley rats (Harlan Teklad, Sprague Dawley, Indianapolis, IN) 
were assigned randomly to individual plastic cages and placed in a room with a 12-h 
light:dark cycle.  Rats were allowed access to food and water ad lib.  Rats were obtained 
at 3-4 wk of age (50-74g) and acclimated for 5 d on an AIN-93 (Harlan Teklad, 
Indianapolis, IN) control diet containing, 10% vitamin free casein, 0.3% L-methionine, 
40.2% corn starch, 39.3 % dextrose, 5% corn oil, 4% mineral mix (AIN-93G-MX), 1% 
vitamin mix (AIN-93-VX), and 2% choline bitartrate (1.5 mol/L) to promote growth.  
Rats were randomly assigned to 4 groups (6 rats per group) fed the following diets: 
control (2 ppm folate), deficient (0 ppm folate), and parallel diets supplemented with 300 
mg/kg diet 99%+ purity genistein (Indofine Chemical Company, Hillsborough, NJ) for an 
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additional 59 d. Cornstarch (0.3 g) was removed from the diet and replaced with 
genistein.    
 At necropsy, non-fasted rats were anesthetized at 5 hr into the light cycle with a 
single intraperitoneal injection of fresh ketamine (135 mg/kg body weight) and zylazine 
(15 mg/kg body weight) mixture. This ratio was adjusted from 90 mg/kg body weight 
ketamine and 10 mg/kg body weight zylazine to prevent additional injections, as 
individual rats respond differently to anesthesia.  Heparinized whole blood samples were 
collected by cardiac puncture and centrifuged at 4000 x g for 6 min upon separation of 
plasma fraction. Plasma samples were frozen at -20°C for subsequent analysis of 
homocysteine concentrations by high performance liquid chromatography (HPLC).   
 One-gram portions of liver were rapidly removed and placed into tubes containing 
4 ml of ice-cold buffer comprised of 10 mM sodium phosphate (pH 7.0), 1 mM EDTA, 
0.25 M sucrose, 1 mM sodium azide, and 0.1 M phenylmethylsulfonyl fluoride.  The 
mixture was homogenized and centrifuged at 20,000 x g at 4°C for 30 min.  The protein 
portion was transferred to 1.5 ml eppendorf tubes and stored at -80°C for later enzyme 
analysis.  The remainder of the liver was removed and placed immediately in liquid 
nitrogen and stored at -80°C for later analysis, including genomic DNA and RNA 
isolation.  One kidney was removed from each animal and homogenized in 1:4 wt/vol 
homogenate buffer as described above and centrifuged at 20,000 x g at 4°C for 30 min. β-
mercaptoethanol was added to each liver and kidney protein fraction at a final 
concentration of 1 mM.  The samples were stored at -80°C for later enzyme analysis.     
Bicinchoninic Acid Protein (BCA) Concentration 
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 Isolated proteinaceous fractions from liver and kidney homogenates were thawed 
on ice and analyzed to determine protein concentration by bicinchoninic acid protein 
(BCA) method (Thermo Scientific, Rockford IL; Pierce Microplate BCA Protein Assay 
Kit).  To adjust for an appropriate standard curve, 2.5 µl instead of 5 µl of protein sample 
was added to each well in triplicate.  Liver and kidney protein isolates were found to be 
more concentrated than protein derived from cell culture, as described by the original 
protocol. Samples were pippeted onto a 96-well plate in triplicate (2.5 µl protein).  
Bovine serum albumin (BSA) was used to establish a standard curve.  The prepared 
standard curve was established by plotting the average blank-corrected value versus its 
concentration (µg/ml) in ascending order from 100% deionized H2O to 100% BSA. In 
addition to protein, 12.5 µl of deionized H2O was added to each well. Approximately 160 
µl of Pierce BCA reagent A and B were added rapidly to each well, including the wells 
containing BSA. Reagent A (stock mixture = 250 µl) contains, sodium bicarbonate, 
sodium carbonate, bicinchoninic acid, and sodium tartarate dissolved in 0.1 M sodium 
hydroxide. Reagent B (stock mixture = 25 ml) contains a 4% cupric sulfate solution.  
Prior to absorbance at 562 nm, the 96-well plate was covered and allowed to sit at room 
temperature for approximately 45 min.    
High Performance Liquid Chromatography  
 Plasma samples were thawed and total plasma homocysteine concentrations were 
determined using methods originally described by (Ubbink et al., 1991).  Approximately 
300 µl of plasma from each sample was spiked with 1 mM N-acetylcysteine and 
incubated at 4°C for 30 min in 1:10 vol/vol of tributylphosphine in dimethylformamide.  
The reaction was terminated by adding 1 mM EDTA dissolved in 10% trichloroacetic 
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acid.  The reaction mixture was centrifuged at 4°C for 5 min at 1000 x g.  The collected 
supernatant was added to tubes containing 0.125 borate buffer (pH 9.5), 1.55 M sodium 
hydroxide, and 0.1% 4-flouro-7-sulfobenzofurazan.  Each sample was filtered using 
aerodisc filters (0.22 µm) prior to injection (100 µl) into the HPLC.  HPLC preparation: 
Samples were analyzed under fluorescence detection using a C-18 column.  The HPLC 
solutions included 0.1 M KH2PO4 buffer (pH 2.1), 100% acetonitrile, and deionized 
water. During the running period, the solutions were adjusted to 96% sodium phosphate 
and 4% acetonitrile.  The flow rate was set at 2.0 ml/min, and pressure was maintained at 
1000-1500 psi.  Chromatograph data indicated that the homocysteine peak occurred at 
approximately 6 min and the N-acetylcysteine peak at approximately 20 min.     
Glycine N-methyltransferase (GNMT) Activity 
 Glycine N-methyltransferase (GNMT) activity was determined by a method 
described by Cook and Wagner.  The experiment was performed on both liver and kidney 
samples. The reaction mixture included 200 mM Tris buffer (pH 9.0), 2 mM glycine, 0.2 
mM S-adenosyl-L-[methyl-3H]methionine, and 5 mM dithiothreitol. The S-adenosyl-L-
[methyl-3H]methionine was made by adding 23 µl (SAM3H) to (10 mM SAM) and 
diluting at 1:10 vol/vol with 10 mM H2S04.  Protein aliquots from each sample, adjusted 
to include 250 µg of protein, were added to separate eppendorf tubes and denatured at 
80°C for 15 min for background analysis. Previously, it was recommended to add 45 µl 
of protein to each tube, denature, and then add an appropriate aliquot to each reaction 
mix. However, isolating the exact amount of protein was found to be difficult because the 
denaturing process dehydrates the sample. The reaction was performed in triplicate with 
one blank. The reaction was initiated by adding each sample to the reaction mix and 
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incubating at 25 °C for 30 min. The reaction was terminated by the addition of 50 µl of 
10% trichloroacetic acid. Upon termination, 250 µl of activated charcoal suspension (78 
mg/ml in 0.1 M acetic acid) was added to each sample and the resulting solution was 
placed in a 4°C refrigerator for 20 min prior to centrifugation at 4°C for 5 min at 13,500 x 
g.  Approximately 200 µl of supernatant from each sample was added to scintillation 
vials containing 10 ml Scintiverse (Fisher Scientific, Fair Lawn, NJ) to determine 
radioactivity by liquid scintillation counting.   
Methionine Synthase (MS) Activity 
 Methionine synthase activity was determined by a method originally described by 
Keating and colleagues.  Resin preparation: 25 g of AG 1-X8 resin (Cl- form, 100-200 
mesh) was suspended in a 1 L beaker and washed 3 times with 300 ml deionized H2O to 
remove impurities.  To prime the resin, 300 ml 0.5 M HCl was added and allowed to rest 
for 90 min, followed by 3 additional rinses with 300 ml deionized H2O.  Next, 300 ml of 
0.5 M sodium hydroxide was added to the resin and rinsed 3 times with 300 ml deionized 
H2O.  Finally, 500 ml of 0.5 M HCl (counterion) was added and decanted and the resin 
was rinsed with 100 ml deionized H2O to remove excess ions.  The resin was vacuum 
filtered (Whatman filter paper) using a Buchner funnel, washed, and stored in deionized 
H2O at room temperature.  Reagents: The reaction mix included the following: freshly 
made 100 mM DL-homocysteine, 1.3 mM cyanocobalamin, 1 M dithiothreitol, 10 mM S-
adenosylmethionine, 82.4 mM 2-mercaptoethanol, 500 mM sodium phosphate buffer (pH 
7.5), 5-CH3-tetrahydrofolate, 5-[14CH3]-tetrahydrofolate (0.25 µCi), and deionized H2O.  
Hepatic protein samples from each rat were diluted with deionized H2O to 600 µg in 100 
µl.  Two samples were denatured at 75°C for 10 min and used as blanks without 100 mM 
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DL-homocysteine.  Each sample (100 µl) was spiked with 100 µl of reaction mix and 
incubated at 37 °C for 1 hour.  The reaction was terminated by the addition of 800 µl of 
ice-cold water, and each sample was added to columns containing approximately 1 ml of 
resin.  The sample was rinsed twice with 1 ml deionized H2O. Scintillation vials were 
labeled A, B, and C for each sample, and effluent was collected as it passed through the 
resin.  The scintillation vials were filled with 10 ml Scintiverse for radioactivity 
determination by liquid scintillation counting.     
Phosphatidylethanolamine N-methyltransferase (PEMT) Activity 
 Approximately 1 gram of liver was isolated from the total liver sample and 
homogenized in 4 ml of 10 mM Tris-HCl (pH 7.4) and 0.25 M sucrose (PEMT buffer).  
The homogenate was centrifuged at 16,000 x g for 20 min at 4°C.  The proteinaceous 
supernatant (1-2 ml) was collected and ultracentrifuged for 1 hour at 105,000 x g at 4°C 
(TLA 100.4 rotor at 50,000 rpm).  The resulting supernatant was discarded and the 
microsomal pellet was resuspended by gentle vortex in approximately 0.5 ml 0.25 M 
sucrose.  Protein concentration was determined by BCA method, and the reaction mixture 
was adjusted to include 750 µg protein in a final volume of 475 µl.  The reaction mixture 
included the following: 10 mM HEPES (pH 7.3), 5 mM MgCl2, 4 mM dithiothreitol 
(DTT), 0.1 mM SAM, 2 µCi S-adenosyl-L-[methyl-3H]methionine, and 750 µg protein.  
The reaction was initiated by adding 75 µl of microsomal protein to the reaction mixture 
(475 µl) and incubated at 37 °C for 10 min.  To terminate the reaction, 100 µl aliquots 
were added in duplicate to closed-glass tubes containing 2 ml of chloroform (1.2 ml), 
methanol (600 µl), and 2 N HCl (200 µl) respectively.  The chloroform phase was 
washed three times with 1 ml 0.5 M KCl dissolved in 50% methanol.  To maintain the 
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chloroform phase after washing samples were centrifuged at 4 °C for 5 min at 1800 x g.  
The remaining chloroform phase was transferred to a glass scintillation vial, and the glass 
washing tube was rinsed three additional times with chloroform to remove any remaining 
lipid fraction.  The chloroform was evaporated overnight, and 5 ml Scintiverse was added 
for radioactivity determination by liquid scintillation counting.       
DNA Isolation and Global Methylation Analysis 
 The method described by Pogribny and colleagues was used to determine relative 
hepatic DNA methylation.  Isolated DNA from each sample was digested with a methyl-
sensitive restriction enzyme exhibiting endonuclease activity for CpG dinucleotides.  
After enzymatic cleavage, the cytosine extension assay was used to determine 3H 
incorporation into staggered DNA fragments.   
DNA isolation (Promega Wizard Genomic DNA Purification Kit, Madison, WI): 
600 µl of Nuclei Lysis Solution was added to a 15 ml tube containing 10-20 mg of 
freshly thawed liver tissue and homogenized.  The lysate was added to a 1.5 ml tube and 
incubated for 20 min at 65 °C at which point 3 µl of RNase solution was added and 
gently mixed.  Upon reaching room temperature, 200 µl of Protein Precipitation Solution 
was added to the solution, vortexed, and cooled on ice.  Each sample was centrifuged for 
4 min at 13,000-16,000 x g and the supernatant, containing the DNA, was transferred to a 
new 1.5 ml eppendorf tube containing 600 µl of 70% ethanol and gently inverted until 
DNA strands were visible to the eye.  The samples were centrifuged for one min at 
13,000-16,000 x g at 4 °C, the supernatant was removed, and the tubes were inverted on 
bench paper to dry for 15 min. DNA Rehydration Solution (100 µl) was added the DNA 
and incubated overnight at 4 °C. DNA purity and concentration for each sample was 
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determined by NanoDrop (Thermo Scientific) method, and the DNA methylation assay 
was adjusted accordingly for each sample (H2O of the reaction mix). Global methylation: 
DNA digestion was performed in triplicate with one blank per sample containing no 
endonuclease.  Each eppendorf tube contained 1.25 µg DNA, 1.25 µl (12.5 U) of HpaII 
endonuclease (5’…C⇓CGG…3’: 3’…GGC⇓C…5’), 2.5 µl 10X NEBuffer 1 (10 mM 
Bis-Tris-Propane-HCL, 10 mM MgCl2, and 1 mM Dithiothreitol) and deionized H2O for 
a total volume of 25 µl.  The tubes were placed in open incubation racks and incubated 
for approximately 16 hr at 37 °C. Each sample was placed on ice to terminate the 
reaction.  Cytosine extension: Briefly, each eppendorf tube contained 20 µl of digested or 
control DNA (1.0 µg; 20 µl), 10X PCR Buffer II w/o MgCl2 (4.0 µl), 25 mM MgCl (1.6 
µl), AmpliTaq DNA Polymerase (0.16 µl), [3H]-dCTP (42.9 Ci/mmol, NEN Life Science 
Products; 0.16 µl), and 14.08 µl deionized H2O.  To prevent evaporation, mineral oil (25 
µl) was added each sample and incubated at 55 °C for 1 hour.  A one in2 grid was 
overlaid on DE81 anion exchange filter paper (Whatman, Piscataway, NJ; 3658-917) and 
30 µl of reaction product was pipetted onto the center of each square and allowed to dry 
for approximately 1 hour.  The filter paper wash washed 3 times for 10 min with 250 ml, 
0.5 M sodium phosphate buffer to remove excess 3H (unbound).  The paper was air dried 
for approximately 3 hr, the grid was cut, and the individual squares were added to 
scintillation vials containing 5 ml Scintiverse for radioactivity determination by liquid 
scintillation counting.      
Quantitative Real Time PCR (qRT-PCR) 
 RNA isolation: Approximately 50-100 mg of liver was isolated and homogenized 
in liquid nitrogen using a mortar and pistol.  The crushed liver was immediately 
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transferred to a 1.5 ml eppendorf tube containing 1 ml of Trizol Reagent (Invitrogen, 
Carlsbad, CA).  The isolate was vortexed and centrifuged at 12,000 x g for 10 min at 4 °C 
t remove insoluble material.  The supernatant was transferred to a new eppendorf tube 
and incubated at 25 °C for 5 min to dissociate nuclease proteins.  Chloroform (200 µl) 
was added to each tube, shaken, incubated for 3 min at room 25 °C, and centrifuged at 
12,000 x g for 15 min at 4 °C. The phenol-chloroform and interphase were discarded, and 
the clear supernatant was transferred to a clean eppendorf tube.  Isopropyl alcohol was 
added to the sample at 1:2 vol/vol of initial Trizol reagent to precipitate the RNA, 
incubated at 25 °C for 10 min, and centrifuged at 12,000 x g for 10 min at 4 °C.  The 
supernatant was discarded, and the RNA pellet was washed with molecular grade 75% 
ethanol (1 ml) 2 times, and stored overnight in molecular grade 100% ethanol at -20 °C to 
remove phenol-contaminants, as determined by NanoDrop (A260/280) method.  The 
ethanol/RNA solution was vortexed and centrifuged at 7500 x g for 5 min at 4 °C, the 
supernatant decanted, and air dried for 5-10 min prior to dissolving in 50 µl of RNase-
free water (Ambion, Austin, TX) and incubating at 55-60 °C for 10 min.  The samples 
were transferred to 0.5 ml eppendorf tubes containing 10X Turbo DNase-free digestion 
buffer and Turbo DNase I and incubated for 30 min at 37 °C (Turbo DNA-free Kit, 
Ambion).  DNase Inactivation Reagent (beads) were added, briefly incubated at 25 °C, 
and centrifuged for 2 min at 10,000 x g.  The RNA-contained supernatant was removed 
and placed in a new 0.5 ml eppendorf tube and stored at -80 °C.  
 Reverse transcriptase (cDNA synthesis): RNA concentrations were determined by 
NanoDrop method to ensure purity.  Approximately 1-2 ug/ul RNA from each sample 
 
   
 
54 
was added to 0.2 ml eppendorf tubes containing 5X iScript reaction mix (Bio-Rad, 
Hercules, CA) Oligo (dt)20 primer, iScript reverse transcriptase, and nuclease-free H2O 
and incubated for 5 min at 25° C, 30 min at 42° C, and 5 min at 85° C.  The cDNA was 
stored at -80° C. Polymerase chain reaction (PCR): cDNA from each sample was diluted 
to approximately 125 ng/µl and 1 µl was added in triplicate to a 96-well plate containing 
10 pmol forward and reverse primers for the individual gene, IQ SYPR Green Supermix 
(Bio-Rad), and diethylpyrocarbonate (DEPC) water.  The completed plate was run using 
the following procedure (MyIQ, Bio-Rad): 3 min at 95° C, 40 cycles for 15 s at 95° C, 30 
s at 60° C, 30 s at 72° C, 1 min at 95° C, 1 min at 55° C, and 80 cycles for 15 s at 55° C.  
The data was analyzed using the Comparative CT method (Table 2.1) (Schmittgen and 
Livak, 2008). 
Western Blot Analysis (Hepatic GNMT and CBS) 
 The protein abundance of GNMT and CBS was determined by immunoblotting 
methods previously described (Rowling and Schalinske, 2001).  Gel preparation: Hepatic 
protein samples were added to eppendorf tubes containing deionized H2O and 2X 
Laemmli Buffer diluted from 4X Laemmli (250 mM Tris HCl, 40% glycerol, 5% SDS, 
0.005% bromophenol blue) and denatured for 15 min at 75 °C. The separating 15% SDS-
polyacrylamide gel was comprised of 1.875 M Tris HCl (pH 8.8), deionized H2O, stock 
acrylamide (30%), SDS (10%), APS (10%), and Temed.  After polymerization, the 
stacking gel (0.6 M Tris HCl; pH 6.8) was loaded, and the gel was run overnight at 7 – 10 
mA using eletrophoresis buffer (250 mM Tris, 192 mM glycine, and 0.1% SDS).  The gel 
casts were separated and the polyacrylamide gels were cut to include the 32-kDa GNMT 
and 63-kDa CBS monomer subunits. Cassette preparation: The buffer was made up of 
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30% transfer buffer (125 mM Tris and 960 mM glycine), 15% methanol, and 55% 
deionized H2O. The cassette was arranged in the following order: cathode (-), 2 pieces of 
Whatman filter paper, SDS-polyacrylamide gel, nitrocellulose membrane, 2 pieces of 
Whatman filter paper, and cathode (+).  The transfer was run at 1 A for 1 hour.  The 
nitrocellulose membranes were blocked for 1 hour at room temperature in Tris-buffered 
saline TTBS (400 ml 5X TBS: 2.5 M NaCl, 100 mM Tris, deionized H2O; 1 ml Tween 20 
and 1600 ml deionized H2O) containing 5% fat-free milk followed by 3 rinses with TTBS 
(15:10:5 min) prior to incubation overnight at 4°C in primary antibody. For GNMT a 
1:40,000 dilution of polyclonal GNMT chicken IgY antibody (Aves Laboratory, #3809, 
Tigard, Oregon) was used as the primary.  For CBS a 1:400 dilution of rabbit IgG 
polyclonal CBS antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was used as the 
primary.  After rinsing with TTBS the nitrocellulose membranes were incubated at room 
temperature for 1 h for CBS with goat-anti rabbit IgG horseradish peroxidase secondary 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and GNMT with goat anti-
chicken IgY horseradish peroxidase secondary antibody (Aves Laboratory, Tigard, 
Oregon).  CBS and GNMT protein abundance was detected by chemiluminescence using 
Kodak-Omat AR film.  Densitometry analysis was performed using Quantity One 
Software (Bio-Rad Laboratories).  
Statistical Analysis  
 Statistical analysis was performed using Sigma Stat software (SPSS, Chicago, 
IL). The mean values for each group were compared using two-way ANOVA at a 
significance level of 5%.  A one-way ANOVA on ranks was used if the normality test 
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failed.  When the ANOVA was significant (P < 0.05), means were compared using 
Fisher’s least significant difference (LSD) procedure.   
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Results 
Experiment 1 
 Creatine and genistein supplementation attenuated elevated plasma homocysteine 
concentrations induced by folate deficiency (Figure 2.2).  Plasma homocysteine 
concentrations were increased by 95% over a 38-d period in rats receiving a folate 
deficient diet (Figure 2.1).  Creatine supplementation (4 g/kg diet) for 10 d reduced 
plasma homocysteine concentrations (16%) in rats fed a folate-deficient diet (p < 0.05). 
Creatine supplemented, control rats tended to have reduced plasma homocysteine 
concentrations (P = 0.08). Genistein (300 mg/kg diet) supplementation did not reduce 
plasma homocysteine concentrations in control-fed rats, but a trend reduction (P = 0.07) 
existed in folate deficient rats fed genistein.  
 Creatine supplemented folate sufficient rats exhibited increased GNMT activity 
compared to folate deficient, creatine-supplemented rats (Figure 2.3).  GNMT activity 
was significantly higher (23%; P < 0.05) in control, creatine supplemented rats compared 
with creatine-supplemented, folate-deficient rats.  GNMT activity was not found to differ 
across the other treatment groups.     
Experiment 2 
 Genistein supplementation attenuated elevated plasma homocysteine 
concentrations induced by folate deficiency (Figure 2.4).  Plasma homocysteine 
concentrations were increased 106% in rats receiving a folate-deficient diet.  Genistein 
(300 mg/kg diet) supplementation for 24 d reduced plasma homocysteine concentrations 
24% in rats fed a folate deficient diet (P < 0.05).  Genistein supplementation did not alter 
the plasma homocysteine concentrations of control fed rats.    
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 Hepatic phosphatidylethanolamine N-methyltransferase (PEMT) activity was not 
altered by folate status or genistein supplementation (Figure 2.5).  Rats were fed either a 
folate-sufficient or deficient diet containing genistein (300 mg/kg diet) for 24 d. 
Phosphatidylethanolamine N-methyltransferase (PEMT) activity was not found to differ 
across the treatment groups. 
 Hepatic methionine synthase (MS) activity was not altered by folate status or 
genistein supplementation (Figure 2.6).  Rats were fed either a folate-sufficient or 
deficient diet containing genistein (300 mg/kg diet) for 24 d. Methionine synthase (MS) 
activity was not found to differ across the treatment groups. 
 Hepatic glycine N-methyltransferase (GNMT) activity was not altered by folate 
status or genistein supplementation (Figure 2.7).  Rats were fed either a folate-sufficient 
or deficient diet containing genistein (300 mg/kg diet) for 24 d. Glycine N-
methyltransferase (GNMT) activity was not found to differ across the treatment groups. 
 Hepatic glycine N-methyltransferase (GNMT) and cystathionine β-synthase 
(CBS) protein abundance were not altered by folate status or genistein supplementation 
(Figure 2.8). Rats were fed either a folate-sufficient or deficient diet containing genistein 
(300 mg/kg diet) for 24 d. Glycine N-methyltransferase (GNMT) and cystathionine β-
synthase (CBS) protein abundance was not found to differ across the treatment groups. 
Experiment 3 
 Genistein supplementation attenuated elevated plasma homocysteine 
concentrations induced by folate deficiency (Figure 2.9).  Plasma homocysteine 
concentrations were increased by 243% over a 59-d period in rats receiving a folate-
deficient diet. Genistein (300 mg/kg diet) supplementation for 59 d reduced plasma 
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homocysteine concentrations by 39% in rats fed a folate deficient-diet (P < 0.05) 
Genistein supplementation did not alter the plasma homocysteine concentrations of 
control-fed rats.  
 Hepatic phosphatidylethanolamine N-methyltransferase (PEMT) activity was not 
altered by folate status or genistein supplementation (Figure 2.10).  Rats were fed either a 
folate-sufficient or deficient diet containing genistein (300 mg/kg diet) for 59 d. 
Phosphatidylethanolamine N-methyltransferase activity was not found to differ across the 
treatment groups. 
 Hepatic methionine synthase (MS) activity was not altered by folate status or 
genistein supplementation (Figure 2.11).  Hepatic methionine synthase activity was not 
altered by folate status or genistein supplementation. Rats were fed either a folate-
sufficient or deficient diet containing genistein (300 mg/kg diet) for 59 d. Methionine 
synthase activity was not found to differ across the treatment groups. 
 Hepatic glycine N-methyltransferase (GNMT) activity was not affected by folate 
status or genistein supplementation (Figure 2.12).  Rats were fed either a folate-sufficient 
or deficient diet containing genistein (300 mg/kg diet) for 59 d. Hepatic GNMT activity 
was not found to differ across the treatment groups. 
 Renal glycine N-methyltransferase (GNMT) activity was not affected by folate 
status or genistein supplementation (Figure 2.13).  Rats were fed either a folate-sufficient 
or deficient diet containing genistein (300 mg/kg diet) for 59 d. Renal GNMT activity 
was not found to differ across the treatment groups. 
 Genomic DNA methylation was not affected by folate status or genistein 
supplementation (Figure 2.14).  Rats were fed either a folate-sufficient or deficient diet 
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containing genistein (300 mg/kg diet) for 59 d. Hepatic genomic methylation patterns 
were not found to differ across the treatment groups. 
 Hepatic glycine N-methyltransferase (GNMT) and cystathionine β-synthase 
(CBS) protein abundance were not altered by folate status or genistein supplementation 
(Figure 2.15).  Rats were fed either a folate-sufficient or deficient diet containing 
genistein (300 mg/kg diet) for 59 d. Hepatic glycine N-methyltransferase and 
Cystathionine β-synthase protein abundance were not found to differ across the treatment 
groups. 
 Neither folate status or genistein supplementation altered gene expression of 
hepatic one-carbon metabolism enzymes (Table 2.2).  Rats were fed either a folate-
sufficient or deficient diet containing genistein (300 mg/kg diet) for 59 d.  Expression of 
hepatic one-carbon metabolism regulatory enzymes was not found to differ across the 
treatment groups. 
 Neither folate status or genistein supplementation altered gene expression of 
hepatic DNA methyltransferase enzymes (Table 2.3).  Rats were fed either a folate-
sufficient or deficient diet containing genistein (300 mg/kg diet) for 59 d.  Expression of 
hepatic DNA methyltransferase enzymes was not found to differ across the treatment 
groups. 
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Discussion 
 Genistein, a 17β-estradiol like phytoestrogen, exhibits a diverse array of 
biological activities, including modulatory actions influencing carcinogenesis and 
vascular pathogenesis (Marini et al., 2009).  Soy isoflavones are consumed in varying 
quantities depending upon the population of interest.  The molecular activities of 
isoflavones associated with disease prevention are complicated due to the diversity of 
human diets (Sacks et al., 2006). Additionally, the specificity of genistein toward 
estrogen receptors, namely the estrogen receptor beta (ER-β), elicits paradoxical effects 
as an agonist or antagonist, depending upon the tissue of interest and concentration of 
genistein treatment (Akiyama et al., 1987; Ye et al., 2009).   
 Previous research investigating the relationship between dietary genistein and 
one-carbon metabolism is limited.  For the first time, we demonstrated through 
independent experiments that dietary administration of genistein at a high but achievable 
intake level (300 mg/kg diet) can attenuate plasma homocysteine concentrations during 
diet-induced folate deficiency.  
 S-adenosylmethionine (SAM), the universal methyl-donor, forms homocysteine 
upon methylating proteins, DNA, phospholipids, and other cellular constituents.  Our 
initial work targeted creatine formation from guanidinoacetate via GAMT as a modulator 
of Homocysteine formation (Silva et al, 2008).  Creatine supplementation reduces the 
endogenous demand on SAM-derived methyl groups, in turn reducing the production of 
Homocysteine (Silva et al., 2009).  Our findings suggested that genistein could also 
independently lower plasma Homocysteine concentrations during diet-induced folate 
deficiency, although not as effectively as creatine supplementation.  Unlike creatine 
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administration, which provides a product of SAM utilization, genistein does not directly 
provide a methyl-group for metabolism.  Genistein may act independently through 
modification of the epigenome, including DNA methylation and histone acetylation, and 
these events may be intertwined with signaling via steroid receptors, namely estrogen 
receptors (Wietzke and Welsh, 2003; Cappelletti et al., 2006).   
 Our analysis of hepatic enzymes that regulate the production and degradation of 
Homocysteine imply that genistein is not altering the activity or expression of these 
enzyme targets. The subtle differences in GNMT activity demonstrated in experiment 2 
(Figure 2.3) during genistein treatment were not supported by changes in protein 
abundance nor were they reproduced in experiment 3 (Figure 2.12, 2.13).  Folate 
deficiency reorganizes the allosteric feedback mechanisms of one-carbon metabolites, 
including the inhibition of 5-methylTHF on GNMT and negative feedback of SAH on 
SAM and SAM on methionine adenosyltransferase (MAT) among others (Grillo and 
Colombatto, 2007).  We would expect the regulation, activity, and production of these 
enzymes to change as folate depletion was exacerbated over time.   
 Chronic folate deficiency or diets lacking choline and methionine deplete cellular 
SAM causing sporadic cancers, including hepatocellular carcinoma, most plausibly due 
to perturbations of DNA methylation and misincorporation of uracil into DNA causing 
double strand breaks, chromosomal damage, and neoplasia (Pogribny et al., 2007).  
Substantially more time is required to produce pathogenesis in a model of moderate 
folate deficiency (Kim et al., 1994).  Our findings that hepatic global methylation patterns 
were not altered by folate status at either 6 or 8 weeks and supports previous findings 
(Kim, 2004). Severe folate deficiency causes global hypomethylation through exhaustion 
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of SAM. However, rodent experiments have documented hypermethylated hepatic 
genomic DNA in animals fed a folate-deficient diet, suggesting hyperactivity of 
perturbed DNA methyltransferase enzymes (Kim, 2004).  Genistein has been shown to 
maintain DNA methylation patterns in prostatic tissue, which expresses ER-β and at the 
same time have no effect on hepatic methylation status within the same animal (Day et 
al., 2002).  The agouti mouse model experiments suggest that genistein is able to correct 
aberrations in fetal programming induced by a methyl-deficient diet, highlighting the 
potential activity of phytoestrogens during gestation (Dolinoy, et al., 2006).  As an 
estrogen-like molecule, genistein may elicit stable alterations in gene expression at 
specific times across the lifespan.        
 Although the mechanisms are not completely understood, folate and genistein 
share similar activities related to chemoprevention, including tyrosine-kinase inhibition, 
which regulates cellular proliferation and apoptosis (Akiyama et al., 1987).  In addition, 
both folate and genistein exhibit antioxidant properties, where folate scavenges oxidative 
radicals and genistein regulates oxidative damage at the level of the vascular endothelium 
in a similar fashion to estradiol (Billon-Gales et al., 2009). Therefore, although certainly 
unique, genistein and folate may overlap in certain regulatory aspects of vascular 
homeostasis and chemoprevention, including Homocysteine metabolism. Folate and 
genistein could mediate the same processes such as DNA methylation independently as 
shown in the agouti mouse model administered genistein during gestation with the 
ultimate effect of mediating one-carbon metabolism and attenuating elevated 
Homocysteine via an unknown mechanism (Dolinoy et al, 2006). Future research will 
aim to further classify the actions of genistein related to one-carbon metabolism.        
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Table 2.1.  Forward and reverse primer sequences for analysis of candidate one-carbon 
metabolism genes (Real-time PCR; Integrated DNA Technologies)    
Genes Forward Primers Reverse Primers 
GNMT  ACA ACA AAG CCC 
ACA TGG TAA CCC 
AGC CGA AAC TTA CTG 
AAG CCA GGA 
PEMT  TGT GCT CTC CAG CTT 
CTA TGC ACT 
AGG GAA ATG TGG 
TCA CTC TGG ACT 
MS TTG GCC TAC CGG ATG 
AAC AAA TGC 
AGC CAC AAA CCT CTT 
GAC TCC TGT 
BHMT ATC TGG GCA GAA 
GGT CAA TGA AGC 
TGA CTC ACA CCT CCT 
GCA ACC AAT 
CBS AAC ATG TTG TCC TCC 
CTG CTT GCT 
TCG GCT TGA ACT GCT 
TGT AGA GGA 
Dnmt-1  TGT GGC AAG AAG 
AAA GGT GGC AAG 
TGG ATG GAC TTG TGG 
GTG TTC TCA 
Dnmt-3a  AGA GTG TCT GGA 
ACA CGG CAG AAT 
TGC TGG TCT TTG CCC 
TGC TTT ATG 
Dnmt-3b  TGC GCC TGC AAG ACT 
TCT TCA CTA 
TGC AGG AAT CGC 
TGG GTA CAA CTT 
18S (Ribosomal RNA) CCA GAG CGA AAG 
CAT TTG CCA AGA 
 
TCG GCA TCG TTT ATG 
GTC GGA ACT 
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Table 2.2.  Relative gene expression of hepatic one-carbon metabolism enzymes in rats 
fed a folate sufficient (Ctrl) or deficient (FD) diet with or without genistein 
supplementation using the comparative CT method. RNA was extracted from hepatic 
samples isolated from the same rats as described in Figure 2.9 and cDNA was 
synthesized as described under “Materials and Methods.” Data is displayed as ΔCt to 
indicate statistical analysis. The Ct value for each sample and gene of interest was 
normalized to the endogenous 18s housekeeping gene. Data are expressed as means ± 
S.E. (n = 6) and P-values of mean comparisons are labeled.     
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Table 2.3.  Relative Gene Expression of hepatic DNA methyltransferase enzymes of rats 
fed a folate sufficient or deficient diet with or without genistein supplementation using 
the comparative Ct method. RNA was extracted from hepatic samples isolated from the 
same rats as described in Figure 2.9 and cDNA was synthesized as described under 
“Materials and Methods.” Data is displayed as ΔCt to indicate statistical analysis. The Ct 
value for each sample and gene of interest was normalized to the endogenous 18s 
housekeeping gene. Data are expressed as means ± S.E. (n = 6) and P-values of mean 
comparisons are labeled.    
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Figure 2.1.  One carbon metabolism and the isoflavone genistein.  
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Figure 2.1.  One-carbon metabolism and the isoflavone genistein. S-adenosylmethionine 
(SAM) is the major biological methyl group donor. SAM-derived methyl groups are 
allocated towards the formation of metabolites, including creatine (Cre) and 
phosphatidylcholine (PC), and for DNA methylation. Tetrahydrofolate (THF) coenzymes 
are required for nucleotide biosynthesis and for the endogenous remethylation of 
homocysteine to form methionine.  Homocysteine accumulates in the absence of 5-
methyltetrahydrofolate and must be either remethylated back to methionine in the 
absence of folate via betaine-homocysteine methyltransferase (BHMT), or irreversibly 
catabolized via the transsulfuration pathway (e.g., cystathionine β-synthase; CBS). 
Hyperhomocysteinemia is an independent risk factor for vascular disease and may reflect 
perturbed cellular methylation potential, which influences DNA methylation, an 
epigenetic phenomenon. Genistein may modulate the formation and degradation of 
Homocysteine, by regulating SAM metabolism, DNA methylation processes, and through 
its paradoxical actions as an estrogen receptor agonist and antagonist. Additional 
abbreviations used are: DHF, dihydrofolate; dUMP, deoxyuridine; dTMP, 
deoxythymidine; TS, thymidylate synthase; GAA, guanidinoacetate; GAMT, 
guanidinoacetate methyltransferase; DMG. Dimethylglycine; SAH, S-
adensylhomocysteine; MTHFR, methylenetetrahydrofolate reductase; MS, methionine 
synthase; Dnmt, DNA methyltransferase; PE, phosphatidylethanolamine. Question marks 
(?) indicate undetermined but proposed interactions of genistein.    
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Figure 2.2.  Plasma homocysteine concentrations from rats fed a folate sufficient (Ctrl) or 
deficient diet (FD) with or without genistein (G) and creatine (Cr) supplementation. Male 
Sprague Dawley rats were obtained at 3-4 wk of age (50-74g) and fed for 28 d on a diet 
containing, 10% vitamin free casein, 0.3% L-methionine, 40.2% corn starch, 39.3 % 
dextrose, 5% corn oil, 4% mineral mix, 2% choline bitartrate (1.5 M), and 1% vitamin 
mix with either 2 ppm folate (folate-sufficient, Ctrl), or 0 ppm folate (folate-deficient, 
FD) for 28 d. On 29 d, parallel diets supplemented with genistein (300mg/kg diet; Ctrl + 
G and FD + G) or 4g/kg diet creatine monohydrate (Ctrl + Cre and FD + Cre) were fed 
for an additional 10 d. On 38 d, blood samples were collected via cardiac puncture, 
centrifuged, and plasma fractions were prepared and analyzed using HPLC, as described 
under “Materials and Methods.” Data are expressed as means ± S.E. (n = 6). Bars with 
different letters denote means that differ (P < 0.05).  
 
   
 
70 
 
Figure 2.3. Glycine N-methyltransferase (GNMT) activity of rats fed a folate sufficient 
(Ctrl) or deficient (FD) diet with or without genistein and creatine supplementation. 
Hepatic samples from the same rats as described in Figure 2.2 were isolated and used to 
determine glycine N-methyltransferase activity as described under “Materials and 
Methods.” Data are expressed as means ± S.E. (n = 6). Bars with different letters denote 
means that differ (P < 0.05).  
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Figure 2.4.  Plasma homocysteine concentrations of rats fed a folate sufficient (Ctrl) or 
deficient diet (FD) with or without genistein supplementation. Male Sprague Dawley rats 
were obtained at 3-4 wk of age (50-74g) and fed for 28 d on a diet containing, 10% 
vitamin free casein, 0.3% L-methionine, 40.2% corn starch, 39.3 % dextrose, 5% corn 
oil, 4% mineral mix, 2% choline bitartrate (1.5 M), and 1% vitamin mix with either 2 
ppm folate (folate-sufficient, Ctrl), or 0 ppm folate (folate-deficient, FD) for 14 d prior to 
supplementation with genistin (300 mg/kg diet) for an additional 24 d. On 38 d, blood 
samples were collected via cardiac puncture, centrifuged, and plasma fractions were 
prepared and analyzed using HPLC, as described under “Materials and Methods.” Data 
are expressed as means ± S.E. (n = 6). Bars with different letters denote means that differ 
(P < 0.05).  
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Figure 2.5.  Phosphatidylethanolamine N-methyltransferase (PEMT) activity of rats fed a 
folate-sufficient (Ctrl) or deficient diet (FD) with or without genistein supplementation. 
Hepatic samples from the same rats as described in Figure 2.4 were isolated and used to 
determine phosphatidylethanolamine N-methyltransferase (PEMT) activity as described 
under “Materials and Methods.” Data are expressed as means ± S.E. (n = 6).  
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Figure 2.6.  Methionine synthase (MS) activity of rats fed a folate sufficient (Ctrl) or 
deficient diet (FD) with or without genistein supplementation. Hepatic samples from the 
same rats as described in Figure 2.4 were isolated and used to determine methionine 
synthase (MS) activity as described under “Materials and Methods.” Data are expressed 
as means ± S.E. (n = 6).  
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Figure 2.7. Glycine N-methyltransferase (GNMT) activity of rats fed a folate sufficient 
(Ctrl) or deficient (FD) diet with or without genistein supplementation. Hepatic samples 
from the same rats as described in Figure 2.4 were isolated and used to determine glycine 
N-methyltransferase activity as described under “Materials and Methods.” Data are 
expressed as means ± S.E. (n = 6). Bars with different letters denote means that differ (P 
< 0.05).  
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Figure 2.8.  Glycine N-methyltransferase (GNMT) and Cystathionine β-synthase (CBS) 
protein abundance of rats fed a folate-sufficient (Ctrl) or deficient (FD) diet with or 
without genistein supplementation. Hepatic samples from the same rats as described in 
Figure 2.4 were isolated and used to determine glycine N-methyltransferase (GNMT) and 
cystathionine β-synthase protein abundance by Western blot analysis as described under 
“Materials and Methods.” Data are expressed as means ± S.E. (n = 6). 
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Figure 2.9.  Plasma homocysteine concentrations of rats fed a folate sufficient (Ctrl) or 
deficient diet (FD) with or without genistein supplementation. Male Sprague Dawley rats 
were obtained at 3-4 wk of age (50-74g) and fed for 5 d on a diet containing, 10% 
vitamin free casein, 0.3% L-methionine, 40.2% corn starch, 39.3 % dextrose, 5% corn 
oil, 4% mineral mix, 2% choline bitartrate (1.5 M), and 1% vitamin mix with 2 ppm 
folate (folate sufficient, Ctrl). On 6 d rats were either maintained on the Ctrl diet or 
folate-deficient diet (FD, 0 ppm folate) with or without genistein (300 mg/kg diet) for an 
additional 59 d. On 64 d, blood samples were collected via cardiac puncture, centrifuged, 
and plasma fractions were prepared and analyzed using HPLC, as described under 
“Materials and Methods.” Data are expressed as means ± S.E. (n = 6). Bars with different 
letters denote means that differ (P < 0.05).  
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Figure 2.10.  Phosphatidylethanolamine N-methyltransferase (PEMT) activity of rats fed 
a folate-sufficient (Ctrl) or deficient diet (FD) with or without genistein supplementation. 
Hepatic samples from the same rats as described in Figure 2.9 were isolated and used to 
determine phosphatidylethanolamine N-methyltransferase (PEMT) activity as described 
under “Materials and Methods.” Data are expressed as means ± S.E. (n = 6).  
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Figure 2.11.  Methionine synthase (MS) activity of rats fed a folate sufficient (Ctrl) or 
deficient (FD) diet with or without genistein supplementation. Hepatic samples from the 
same rats as described in Figure 2.9 were isolated and used to determine methionine 
synthase (MS) activity as described under “Materials and Methods.” No significant 
differences were found in MS activity between folate status or genistein supplementation. 
Data are expressed as means ± S.E. (n = 6).  
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Figure 2.12.  Hepatic glycine N-methyltransferase (GNMT) activity of rats fed a folate-
sufficient (Ctrl) or deficient (FD) diet with or without genistein supplementation. Hepatic 
samples from the same rats as described in Figure 2.9 were isolated and used to 
determine hepatic glycine N-methyltransferase activity as described under “Materials and 
Methods.” Data are expressed as means ± S.E. (n = 6).  
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Figure 2.13.  Renal glycine N-methyltransferase (GNMT) activity of rats fed a folate-
sufficient (Ctrl) or deficient (FD) diet with or without genistein supplementation. Whole 
kidney samples from the same rats as described in Figure 2.9 were excised and prepared 
to determine renal glycine N-methyltransferase (GNMT) activity as described under 
“Materials and Methods.” Data are expressed as means ± S.E. (n = 6).  
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Figure 2.14.  Genomic DNA methylation of rats fed a folate-sufficient (Ctrl) or deficient 
(FD) diet with or without genistein supplementation. Hepatic samples from the same rats 
as described in Figure 2.9 were obtained and DNA was isolated to determine genomic 
DNA methylation as described under “Materials and Methods.” Data are expressed as 
means ± S.E. (n = 6).  
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Figure 2.15.  Glycine N-methyltransferase (GNMT) and cystathionine β-synthase (CBS) 
protein abundance of rats fed a folate-sufficient (Ctrl) or deficient (FD) diet with or 
without genistein supplementation. Hepatic samples from the same rats as described in 
Figure 2.9 were isolated and used to determine glycine N-methyltransferase (GNMT) and 
cystathionine β-synthase protein abundance by Western blot analysis as described under 
“Materials and Methods.” Data are expressed as means ± S.E. (n = 6).   
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CHAPTER 3. GENERAL CONCLUSIONS 
  In this thesis, I have elucidated further the actions of the bioactive 
phytoestrogen genistein in relation to perturbations in one-carbon metabolism caused by 
diet induced folate deficiency.  Chronic folate deficiency poses significant risks that 
include vascular disease, neurological disorders, birth defects, certain cancers, and 
diminished physiological performance due to anemia and growth retardation (Beaudin 
and Stover, 2007).  Mandatory fortification of cereals and grains in the late 1990s 
dramatically reduced the incidence of neural tube defects and also increased the 
circulating concentration of 5-methylTHF across the population of the United States.  
However, folate status varies among individuals and particularly within those who 
display polymorphic variation in the genes regulating folate metabolism such as those 
encoding methylene tetrahydrofolate reductase (MTHFR) and cystathionine β-synthase 
(CBS).  Gene variation in the MTHFR enzyme is believed to exist in upwards of 15% of 
the population and the associated risk factors appear to be highly dependent upon folate 
status as demonstrated through reduced enzyme function (Dowey et al., 2004).  
 Homeostatic one-carbon metabolism is dependent upon a number of substrates 
and cofactors other than folate that include vitamins B12, B6, and B2 and the methyl-
providers betaine, choline, and methionine (Verhoef et al., 1996).  There are numerous 
ways to perturb cellular methylation potential in an experimental model, including 
providing a diet with a defined amino acid profile or depleting the diet of any of the 
multiple aforementioned constituents (Wilcken and Wilcken, 1998).  Our research model 
produced a state of moderate folate deficiency through depletion of dietary folate without 
antibiotic treatment.  Antibiotics prevent folate synthesis by gut flora exacerbating folate 
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losses and depleting hepatic choline pools due in part to increased folate independent 
remethylation of homocysteine via betaine homocysteine methyltransferase (BHMT). 
Hepatic choline and phosphatidylcholine stores are reduced by 65% and 85% 
respectively at 4 weeks in animals fed a folate deplete diet with antibiotics.  However, 
rats subjected to moderate folate deficiency exhibit only a 30% reduction in hepatic 
choline stores at 24 weeks (Kim et al, 1994).  Severe folate deficiency is now rare in 
industrialized countries, and our model aimed to represent a subset of the population with 
altered folate metabolism or inconsistent intake.  
 In each of my studies we demonstrated a consistent and dramatic increase in 
plasma homocysteine concentration caused by folate restriction without changes in 
enzyme function. Plasma homocysteine concentrations reflect the global folate 
metabolism of an animal, including transmethylation, remethylation, and transsulfuration 
pathways (Hazra et al., 2009).  The liver accounts for nearly 80% of SAM utilization, and 
although I did not see changes in expression or abundance of one-carbon metabolism 
enzymes, we expect that ultimately this tightly regulated network would reflect depleted 
folate pools.  For example, 5-methylTHF is an allosteric inhibitor of glycine N-
methyltransferase (GNMT) and, therefore folate deficiency, would eventually alleviate 
this inhibition.  Similarly, CBS activity would increase to enhance the catabolism of 
accumulating homocysteine within the cell.  Folate independent remethylation of 
homocysteine via BHMT would compensate for the reduced formation of 5-methylTHF, 
depleting choline pools and altering the activity of phosphatidylethanolamine N-
methyltransferase (PEMT), a major consumer of SAM-derived methyl groups (Wagner, 
2005).   
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 Hyperhomocysteinemia is an independent risk factor for cardiovascular disease 
(Aguilar et al., 2004). Homocysteine promotes endothelial damage, platelet aggregation, 
thrombosis, inflammation, and lipid/LDL oxidation.  The associated rise of 
homocysteine, common in vascular disease patients, is not completely understood and 
may actually represent a marker for more severe cellular alterations including reduced 
cellular methylation potential, which causes DNA hypomethylation, double strand 
breaks, and chromosomal damage (Duthie et al., 2002). In my preliminary study, I 
hypothesized that supplementation with creatine monohydrate would reduce the 
endogenous demand on SAM in a folate deficient model.  The work done by Brosnan and 
colleagues demonstrated that administration of guanidinoacetate increases plasma 
homocysteine concentrations, while creatine supplementation attenuates basal 
homocysteine concentrations (Stead et al., 2001).  To our knowledge, we are the first to 
demonstrate that creatine supplementation can decrease plasma homocysteine 
concentrations in a folate-deficient rat model.  We speculate that this effect is mediated 
through reduced activity of hepatic guanidinoacetate methyltransferase (GAMT) and 
renal L-arginine: glycine amidinotransferase, which form creatine and guanidinoacetate 
respectively (Silva et al., 2008).   
 During our initial work we also investigated the effects of genistein 
administration on one-carbon metabolism.  Previous research indicates that genistein can 
alter methylation patterns in the agouti mouse model fed a methyl-deficient diet, 
preventing fetal imprinting (e.g., hypomethylation) which predisposes the animal to 
various disease states (Dolinoy et al., 2006).  Soy isoflavones have been implicated in the 
prevention of various diseases, largely based on differences between population studies 
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or alternately ex vivo work with pharmacological treatments.  The role of phytoestrogens 
in disease prevention is controversial due to both the multitude of confounding factors of 
a normal human diet (i.e., soy protein and lipid composition) and the potential deleterious 
actions of estrogen-like compounds, including the promotion of estrogen-responsive 
cancers (Ye et al., 2009).  We have demonstrated that genistein is able to reduce 
hyperhomocysteinemia caused by diet-induced folate deficiency across various time 
points of folate restriction and genistein supplementation.  We have yet to classify a 
consistent modification of the enzymes regulating one-carbon metabolism, which would 
cause the reduction in plasma homocysteine concentrations.  Conceivably, genistein may 
be acting at a greater efficiency in estrogen-responsive tissues such as the testes and 
prostate, where ER-β is expressed at a higher level than within the liver (Cappelletti et al, 
2006).  It is also possible that genistein may be functioning to a greater extent in the 
kidney, where a significant portion of SAM metabolism occurs.  My major work 
involved the investigation of hepatic transmethylation, remethylation, and 
transsulfuration enzymes, however, many questions need to be addressed in future 
research.  
 First and foremost, I have not yet determined the metabolic target of genistein as 
it relates to homocysteine metabolism.  Research has demonstrated that genistein may 
alter the activity of DNA methyltransferase enzymes, which although certainly relevant, 
does not completely explain the considerable reduction in plasma homocysteine, as total 
DNA methylation is believed to account for less than 20% of SAM utilization.  My 
analysis of hepatic global methylation did not shed light on this interaction because our 
model of folate deficiency did not induce hepatic genomic hypomethylation.  However, it 
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is possible that genistein is acting at a more specific level than genomic methylation 
maintenance or at a higher affinity in estrogen-responsive tissues.  Genistein could be 
indirectly regulating one-carbon metabolism as an estrogen-like molecule, independently 
of folate.  The structural nature of genistein allows it to interact not only with ER-β but 
also the vitamin D receptor (VDR) and the retinoid X receptor (RXR) (Weitzke and 
Welsh, 2003).  Future research should investigate potential hormonal interactions to 
determine if genistein is acting via alternative mechanisms.  
 It would be interesting to conduct a similar experiment using a fetal-programming 
model, where pregnant rats are fed a folate-restricted diet supplemented with genistein 
and transmethylation, remethylation, and transsulfuration enzyme function was evaluated 
as well as alterations in DNA methylation in and beyond hepatic tissue.  Based on the 
agouti mouse studies demonstrating alterations in the epigenome independent of folate, I 
could determine if these changes alter methionine metabolism or specifically DNA 
methyltransferases (Dolinoy et al., 2006).  It appears that in utero or early post-natal 
exposure to environmental factors and nutrients plays a pivotal role in the development 
and disease susceptibility of an animal and these effects become diluted as the animal 
ages (Liu et al., 2008).  Targeting specific genes of interest would provide a greater 
understanding of early epigenetic regulation by genistein.  It is possible that the 
regulatory elements of enzymes functioning to mediate one-carbon metabolism are within 
those influenced by genistein or distant regulation is modulating the enzymes of interest, 
as DNA methylation and histone acetylation regulate transcription beyond their 
immediate locations (Stover, 2009).  I have demonstrated for the first time that genistein 
is able to attenuate plasma homocysteine concentrations in rats caused by dietary folate 
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depletion.  My future work will aim to determine how genistein modifies the production 
and or degradation homocysteine through its mediation of one-carbon metabolism.    
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